BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420. [PMID: 19934295 DOI: 10.1158/1078-0432.ccr-09-1624] [Cited by in Crossref: 2116] [Cited by in F6Publishing: 1079] [Article Influence: 162.8] [Reference Citation Analysis]
Number Citing Articles
1 Feld E, Horn L. Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. Onco Targets Ther 2017;10:3697-708. [PMID: 28769573 DOI: 10.2147/OTT.S97903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, Sharma A, Garbe C, Singh P, Mehnert JM. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer 2019;121:417-20. [PMID: 31353364 DOI: 10.1038/s41416-019-0530-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
3 He Y, de Araújo Júnior RF, Cruz LJ, Eich C. Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy. Pharmaceutics 2021;13:1670. [PMID: 34683963 DOI: 10.3390/pharmaceutics13101670] [Reference Citation Analysis]
4 Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655-670. [PMID: 31908886 DOI: 10.20892/j.issn.2095-3941.2019.0144] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
5 Madonna G, Masucci GV, Capone M, Mallardo D, Grimaldi AM, Simeone E, Vanella V, Festino L, Palla M, Scarpato L, Tuffanelli M, D'angelo G, Villabona L, Krakowski I, Eriksson H, Simao F, Lewensohn R, Ascierto PA. Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers (Basel) 2021;13:4164. [PMID: 34439318 DOI: 10.3390/cancers13164164] [Reference Citation Analysis]
6 Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, Rübenthaler J, Brendel M, Subklewe M, von Bergwelt-Baildon M, Ricke J, Kunz WG, Cyran CC. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 2020;4:63. [PMID: 33200246 DOI: 10.1186/s41747-020-00190-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
7 Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2015;28:135-47. [PMID: 25113308 DOI: 10.1111/pcmr.12304] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
8 Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM. Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res 2017;23:5737-44. [PMID: 28679767 DOI: 10.1158/1078-0432.CCR-17-1434] [Cited by in Crossref: 52] [Cited by in F6Publishing: 24] [Article Influence: 10.4] [Reference Citation Analysis]
9 Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K, Ogata M, Nomura S. Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 2018;9:32298-304. [PMID: 30190787 DOI: 10.18632/oncotarget.25949] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
10 Ahuja J, Shroff GS, Strange CD, Vlahos I, Benveniste MFK, Truong MT. Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer. Semin Ultrasound CT MR 2021;42:552-62. [PMID: 34895611 DOI: 10.1053/j.sult.2021.04.015] [Reference Citation Analysis]
11 Zang H, Peng J, Zheng H, Fan S. Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses. Front Oncol 2020;10:515. [PMID: 32411591 DOI: 10.3389/fonc.2020.00515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013;5:208ra147. [PMID: 24154601 DOI: 10.1126/scitranslmed.3006941] [Cited by in Crossref: 150] [Cited by in F6Publishing: 140] [Article Influence: 18.8] [Reference Citation Analysis]
13 Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015;145:182-201. [PMID: 25826229 DOI: 10.1111/imm.12459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
14 Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013;2:899-906. [PMID: 24403263 DOI: 10.1002/cam4.140] [Cited by in Crossref: 191] [Cited by in F6Publishing: 174] [Article Influence: 21.2] [Reference Citation Analysis]
15 Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267. [PMID: 26605313 DOI: 10.3978/j.issn.2305-5839.2015.10.27] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
16 Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer 2019;7:80. [PMID: 30894212 DOI: 10.1186/s40425-019-0562-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
17 Blumenthal GM, Zhang L, Zhang H, Kazandjian D, Khozin S, Tang S, Goldberg K, Sridhara R, Keegan P, Pazdur R. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. JAMA Oncol 2017;3:e171029. [PMID: 28617920 DOI: 10.1001/jamaoncol.2017.1029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
18 de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab 2016;101:4431-9. [PMID: 27571185 DOI: 10.1210/jc.2016-2300] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 18.0] [Reference Citation Analysis]
19 Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64:842-848. [PMID: 25666193 DOI: 10.1136/gutjnl-2014-307990] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 13.9] [Reference Citation Analysis]
20 Brewer KD, DeBay DR, Dude I, Davis C, Lake K, Parsons C, Rajagopalan R, Weir G, Stanford MM, Mansour M, Bowen CV. Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget 2016;7:35655-69. [PMID: 27232944 DOI: 10.18632/oncotarget.9580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 2018;9:1591. [PMID: 29686284 DOI: 10.1038/s41467-018-03900-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
22 Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805-812. [PMID: 22020206 DOI: 10.1038/nrc3153] [Cited by in Crossref: 413] [Cited by in F6Publishing: 384] [Article Influence: 37.5] [Reference Citation Analysis]
23 Guo H, He Y, Chen P, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, Zhou C. Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation? J Thorac Dis 2020;12:6070-89. [PMID: 33209440 DOI: 10.21037/jtd-20-1689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014;2:40. [PMID: 25411640 DOI: 10.1186/s40425-014-0040-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
25 Nguyen T, Urban J, Kalinski P. Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014;3:135-50. [PMID: 27471705 DOI: 10.2147/ITT.S40264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Barat M, Guegan-Bart S, Cottereau AS, Guillo E, Hoeffel C, Barret M, Gaujoux S, Dohan A, Soyer P. CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies. Abdom Radiol (NY) 2021;46:2219-35. [PMID: 33135115 DOI: 10.1007/s00261-020-02837-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014;33:641-55. [PMID: 24477411 DOI: 10.1007/s10555-013-9479-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
28 Slingluff CL, Zarour HM, Tawbi HA, Kirkwood JM, Postow MA, Friedlander P, Devoe CE, Gaughan EM, Mauldin IS, Olson WC, Smith KT, Macri MJ, Ricciardi T, Ryan A, Venhaus R, Wolchok JD. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology 2021;10:1898105. [PMID: 33796406 DOI: 10.1080/2162402X.2021.1898105] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, Postow MA, Ariyan C. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine 2017;18:56-61. [PMID: 28356222 DOI: 10.1016/j.ebiom.2017.03.029] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
30 Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist 2015;20:648-52. [PMID: 25964307 DOI: 10.1634/theoncologist.2014-0468] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
31 Nakhoda SK, Olszanski AJ. Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceut Med 2020;34:83-91. [PMID: 32157638 DOI: 10.1007/s40290-020-00326-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571. [PMID: 25428505 DOI: 10.1038/nature13954] [Cited by in Crossref: 3422] [Cited by in F6Publishing: 3190] [Article Influence: 488.9] [Reference Citation Analysis]
33 Medina PJ, Adams VR. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy 2016;36:317-34. [PMID: 26822752 DOI: 10.1002/phar.1714] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
34 de Castro J, Cobo M, Isla D, Puente J, Reguart N, Cabeza B, Gayete A, Sánchez M, Torres MI, Ferreirós J. Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015;17:11-23. [PMID: 25373531 DOI: 10.1007/s12094-014-1231-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Aggarwal C, Borghaei H. Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. Oncologist 2017;22:700-8. [PMID: 28408617 DOI: 10.1634/theoncologist.2016-0345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
36 Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016;3:11. [PMID: 27904752 DOI: 10.1186/s40661-016-0033-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
37 Oliveira LJC, Gongora ABL, Barbosa FG, Dos Anjos CH, Munhoz RR. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. J Immunother Cancer 2018;6:130. [PMID: 30482243 DOI: 10.1186/s40425-018-0444-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clin Cancer Res 2017;23:4980-91. [PMID: 28864726 DOI: 10.1158/1078-0432.CCR-16-3064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
39 Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, Katsurada N, Tachihara M, Kobayashi K, Nishimura Y. Pseudo-Progression and the Neutrophil-to-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Case-Control Study. Onco Targets Ther 2019;12:10559-68. [PMID: 31819535 DOI: 10.2147/OTT.S228138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
40 Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 2016;22:117-20. [PMID: 27111907 DOI: 10.1097/PPO.0000000000000176] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
41 Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24:2174-2180. [PMID: 23666915 DOI: 10.1093/annonc/mdt161] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 13.8] [Reference Citation Analysis]
42 Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92. [PMID: 24163750 DOI: 10.3978/j.issn.2072-1439.2013.08.52] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
43 Espinosa E, Berrocal A, López Martín JA, González Cao M, Cerezuela P, Mayordomo JI, Martín Algarra S; Grupo Español de Melanoma (GEM). Advances in cutaneous melanoma. Clin Transl Oncol 2012;14:325-32. [PMID: 22551537 DOI: 10.1007/s12094-012-0804-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, Mohanakumar T, Frazier WA, Lin Y, Chapman WC. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 2015;360:302-9. [PMID: 25721088 DOI: 10.1016/j.canlet.2015.02.036] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 9.9] [Reference Citation Analysis]
45 Winkler JK, Buder-Bakhaya K, Dimitrakopoulou-Strauss A, Enk A, Hassel JC. [Malignant melanoma : Current status]. Radiologe 2017;57:814-21. [PMID: 28730266 DOI: 10.1007/s00117-017-0281-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
46 Joseph RW, Chatta G, Vaishampayan U. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. Urol Oncol 2017;35:142-8. [PMID: 28259541 DOI: 10.1016/j.urolonc.2017.01.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
47 Bloom JE, McNeel DG, Olson BM. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines 2012;11:1401-4. [PMID: 23252384 DOI: 10.1586/erv.12.122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
48 Schweighofer-Zwink G, Manafi-Farid R, Kölblinger P, Hehenwarter L, Harsini S, Pirich C, Beheshti M. Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. Eur J Radiol 2022;146:110107. [PMID: 34922117 DOI: 10.1016/j.ejrad.2021.110107] [Reference Citation Analysis]
49 Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment. J Immunother Cancer 2016;4:30. [PMID: 27330803 DOI: 10.1186/s40425-016-0134-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
50 Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936-3943. [PMID: 23743568 DOI: 10.1158/1078-0432.ccr-13-0895] [Cited by in Crossref: 291] [Cited by in F6Publishing: 142] [Article Influence: 32.3] [Reference Citation Analysis]
51 Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014;12:116. [PMID: 24885479 DOI: 10.1186/1479-5876-12-116] [Cited by in Crossref: 120] [Cited by in F6Publishing: 111] [Article Influence: 15.0] [Reference Citation Analysis]
52 Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015;33:1191-6. [PMID: 25713437 DOI: 10.1200/JCO.2014.56.6018] [Cited by in Crossref: 310] [Cited by in F6Publishing: 152] [Article Influence: 44.3] [Reference Citation Analysis]
53 Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-3198. [PMID: 26282644 DOI: 10.1200/jco.2015.60.8448] [Cited by in Crossref: 593] [Cited by in F6Publishing: 282] [Article Influence: 84.7] [Reference Citation Analysis]
54 Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 2018;6:74. [PMID: 30012216 DOI: 10.1186/s40425-018-0383-1] [Cited by in Crossref: 109] [Cited by in F6Publishing: 116] [Article Influence: 27.3] [Reference Citation Analysis]
55 Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res 2016;22:1364-70. [PMID: 26534966 DOI: 10.1158/1078-0432.CCR-15-0491] [Cited by in Crossref: 156] [Cited by in F6Publishing: 75] [Article Influence: 22.3] [Reference Citation Analysis]
56 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
57 Chen MY, Zeng YC. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol 2021;169:103531. [PMID: 34800651 DOI: 10.1016/j.critrevonc.2021.103531] [Reference Citation Analysis]
58 Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist 2017;22:1232-7. [PMID: 28652280 DOI: 10.1634/theoncologist.2017-0133] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
59 Lau D, McLean MA, Priest AN, Gill AB, Scott F, Patterson I, Carmo B, Riemer F, Kaggie JD, Frary A, Milne D, Booth C, Lewis A, Sulikowski M, Brown L, Lapointe JM, Aloj L, Graves MJ, Brindle KM, Corrie PG, Gallagher FA. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma. J Immunother Cancer 2021;9:e003125. [PMID: 34561275 DOI: 10.1136/jitc-2021-003125] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ, Kambadakone A. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol 2018;91:20170457. [PMID: 29172675 DOI: 10.1259/bjr.20170457] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
61 Calandri M, Solitro F, Angelino V, Moretti F, Veltri A. The role of radiology in the evaluation of the immunotherapy efficacy. J Thorac Dis 2018;10:S1438-46. [PMID: 29951295 DOI: 10.21037/jtd.2018.05.130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
62 Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. Oncotarget 2018;9:8706-15. [PMID: 29492229 DOI: 10.18632/oncotarget.24283] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
63 Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36. [PMID: 26288737 DOI: 10.1186/s40425-015-0078-9] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
64 Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med 2017;58:1421-8. [PMID: 28360208 DOI: 10.2967/jnumed.116.188839] [Cited by in Crossref: 129] [Cited by in F6Publishing: 103] [Article Influence: 25.8] [Reference Citation Analysis]
65 Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 2017;28:1988-95. [PMID: 28595336 DOI: 10.1093/annonc/mdx190] [Cited by in Crossref: 151] [Cited by in F6Publishing: 147] [Article Influence: 37.8] [Reference Citation Analysis]
66 Cai WL, Hong GB. Quantitative image analysis for evaluation of tumor response in clinical oncology. Chronic Dis Transl Med 2018;4:18-28. [PMID: 29756120 DOI: 10.1016/j.cdtm.2018.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011;19:1913-22. [PMID: 21772252 DOI: 10.1038/mt.2011.132] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 9.1] [Reference Citation Analysis]
68 Novik AV, Danilova AB, Sluzhev MI, Nehaeva TL, Larin SS, Girdyuk DV, Protsenko SA, Semenova AI, Danilov AO, Moiseyenko VM, Georgiev GP, Baldueva IA. An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer. Oncologist 2020;25:e1303-17. [PMID: 32240562 DOI: 10.1634/theoncologist.2020-0160] [Reference Citation Analysis]
69 Wiater K, Switaj T, Mackiewicz J, Kalinka-Warzocha E, Wojtukiewicz M, Szambora P, Falkowski S, Rogowski W, Mackiewicz A, Rutkowski P. Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn) 2013;17:257-62. [PMID: 24596511 DOI: 10.5114/wo.2013.35785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
70 Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol. 2013;31:191-199. [PMID: 23438382 DOI: 10.1016/j.clindermatol] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers (Basel) 2021;13:E168. [PMID: 33418936 DOI: 10.3390/cancers13020168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015;7:1073-104. [PMID: 26598957 DOI: 10.2217/imt.15.75] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
73 Buyse M, Saad ED, Burzykowski T, Péron J. Assessing Treatment Benefit in Immuno-oncology. Stat Biosci 2020;12:83-103. [DOI: 10.1007/s12561-020-09268-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014;15:658-69. [PMID: 25096781 DOI: 10.1007/s11864-014-0305-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
75 Grecea M, Marabelle A, Ammari S, Massard C, Champiat S. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. Oncologist 2020;25:369-74. [PMID: 32091646 DOI: 10.1634/theoncologist.2019-0671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
76 Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B. Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Curr Oncol 2021;28:3227-39. [PMID: 34449592 DOI: 10.3390/curroncol28050280] [Reference Citation Analysis]
77 Choe J, Braschi-amirfarzan M, Tirumani SH, Shinagare AB, Kim KW, Ramaiya NH, Krajewski KM. Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Abdom Radiol 2017;42:2710-24. [DOI: 10.1007/s00261-017-1195-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Lee JH, Shklovskaya E, Lim SY, Carlino MS, Menzies AM, Stewart A, Pedersen B, Irvine M, Alavi S, Yang JYH, Strbenac D, Saw RPM, Thompson JF, Wilmott JS, Scolyer RA, Long GV, Kefford RF, Rizos H. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun 2020;11:1897. [PMID: 32312968 DOI: 10.1038/s41467-020-15726-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
79 Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013;15:98-104. [PMID: 23263823 DOI: 10.1007/s11912-012-0284-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
80 Bai R, Li W, Du N, Cui J. Challenges of evaluating immunotherapy efficacy in solid tumors. Chin J Cancer Res 2019;31:853-61. [PMID: 31949388 DOI: 10.21147/j.issn.1000-9604.2019.06.02] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
82 Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA. PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncoimmunology 2018;7:e1405206. [PMID: 30524879 DOI: 10.1080/2162402X.2017.1405206] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
83 van Dinther D, Stolk DA, van de Ven R, van Kooyk Y, de Gruijl TD, den Haan JMM. Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukoc Biol 2017;102:1017-34. [PMID: 28729358 DOI: 10.1189/jlb.5MR0217-059RR] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
84 Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA, McEwan P, Wagner S, Borrill J, Wu E. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer 2020;8:e000648. [PMID: 32661115 DOI: 10.1136/jitc-2020-000648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51. [PMID: 27660705 DOI: 10.1186/s40425-016-0156-7] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 37.8] [Reference Citation Analysis]
86 Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 2021;24:946-58. [PMID: 33743112 DOI: 10.1007/s10120-021-01173-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
87 Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL. Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol 2014;34:399-432. [PMID: 25404047 DOI: 10.1615/critrevimmunol.2014011577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
88 Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019;7:184. [PMID: 31307547 DOI: 10.1186/s40425-019-0662-5] [Cited by in Crossref: 149] [Cited by in F6Publishing: 137] [Article Influence: 49.7] [Reference Citation Analysis]
89 Chmielowski B. Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. J Skin Cancer 2013;2013:423829. [PMID: 23738073 DOI: 10.1155/2013/423829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
90 Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015;13:102. [PMID: 25890361 DOI: 10.1186/s12967-015-0460-x] [Cited by in Crossref: 148] [Cited by in F6Publishing: 149] [Article Influence: 21.1] [Reference Citation Analysis]
91 Asmar R, Yang J, Carvajal RD. Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016;12:313-25. [PMID: 27013881 DOI: 10.2147/TCRM.S78039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
92 Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 2016;536:91-5. [PMID: 27350335 DOI: 10.1038/nature18945] [Cited by in Crossref: 249] [Cited by in F6Publishing: 223] [Article Influence: 41.5] [Reference Citation Analysis]
93 Gao L, Yang X, Yi C, Zhu H. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Front Pharmacol 2019;10:1173. [PMID: 31680957 DOI: 10.3389/fphar.2019.01173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
94 Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. J Immunother Cancer 2020;8:e000368. [PMID: 32376721 DOI: 10.1136/jitc-2019-000368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Lu L, Yan H, Shyam-Sundar V, Janowitz T. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014;8:1539-53. [PMID: 25302014 DOI: 10.2147/DDDT.S65963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
96 Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, Cognetti F, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014;118:109-16. [PMID: 24532241 DOI: 10.1007/s11060-014-1400-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 55] [Article Influence: 2.5] [Reference Citation Analysis]
97 Waxman ES, Lee Gerber D. Pseudoprogression and Immunotherapy Phenomena. J Adv Pract Oncol 2020;11:723-31. [PMID: 33575068 DOI: 10.6004/jadpro.2020.11.7.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Guo CX, Huang X, Xu J, Zhang XZ, Shen YN, Liang TB, Bai XL. Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases 2021; 9(26): 7643-7652 [PMID: 34621816 DOI: 10.12998/wjcc.v9.i26.7643] [Reference Citation Analysis]
99 Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70. [PMID: 23032743 DOI: 10.1158/1078-0432.CCR-12-1177] [Cited by in Crossref: 260] [Cited by in F6Publishing: 159] [Article Influence: 26.0] [Reference Citation Analysis]
100 Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 2019;21:26-36. [PMID: 30137421 DOI: 10.1093/neuonc/noy137] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 20.0] [Reference Citation Analysis]
101 Orange M, Reuter U, Hobohm U. Coley's Lessons Remembered: Augmenting Mistletoe Therapy. Integr Cancer Ther 2016;15:502-11. [PMID: 27207233 DOI: 10.1177/1534735416649916] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
102 Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm. 2010;25:601-613. [PMID: 21204754 DOI: 10.1089/cbr.2010.0865] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 8.5] [Reference Citation Analysis]
103 Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780. [PMID: 25083318 DOI: 10.4161/onci.28780] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 28.4] [Reference Citation Analysis]
104 Bilusic M, Heery C, Madan RA. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine 2011;29:6485-97. [PMID: 21741424 DOI: 10.1016/j.vaccine.2011.06.088] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
105 Marciscano AE, Thorek DLJ. Role of noninvasive molecular imaging in determining response. Adv Radiat Oncol 2018;3:534-47. [PMID: 30370353 DOI: 10.1016/j.adro.2018.07.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
106 Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A 2020;117:28960-70. [PMID: 33127761 DOI: 10.1073/pnas.2013644117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
107 Zhao X, Kong Y, Zhang L. Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. Front Oncol 2020;10:1625. [PMID: 33014817 DOI: 10.3389/fonc.2020.01625] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Mitchell PL, Quinn MA, Grant PT, Allen DG, Jobling TW, White SC, Zhao A, Karanikas V, Vaughan H, Pietersz G, McKenzie IF, Gargosky SE, Loveland BE. A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. J Immunother Cancer 2014;2:16. [PMID: 24995129 DOI: 10.1186/2051-1426-2-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
109 Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 2016;375:819-29. [PMID: 27433843 DOI: 10.1056/NEJMoa1604958] [Cited by in Crossref: 1500] [Cited by in F6Publishing: 899] [Article Influence: 250.0] [Reference Citation Analysis]
110 Formenti SC, Hawtin RE, Dixit N, Evensen E, Lee P, Goldberg JD, Li X, Vanpouille-Box C, Schaue D, McBride WH, Demaria S. Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. J Immunother Cancer 2019;7:177. [PMID: 31296256 DOI: 10.1186/s40425-019-0633-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
111 Wang XY, Zuo D, Sarkar D, Fisher PB. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 2011;12:2695-706. [PMID: 22077831 DOI: 10.1517/14656566.2011.629187] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
112 Zheng B, Shin JH, Li H, Chen Y, Guo Y, Wang M. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy. Korean J Radiol 2021;22:366-75. [PMID: 33289356 DOI: 10.3348/kjr.2020.0404] [Reference Citation Analysis]
113 Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97-106. [PMID: 25755682 DOI: 10.1177/1758834014567469] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 13.4] [Reference Citation Analysis]
114 Guidance Development Review Committee., Working Group for Clinical Studies of Cancer Immunotherapy., Working Group for Effector Cell Therapy., Working Group for CMC/Non-clinical Studies., Working Group for Cancer Vaccines and Adjuvants., Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy., Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci 2015;106:1761-71. [PMID: 26767933 DOI: 10.1111/cas.12819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
115 Russo L, Avesani G, Gui B, Trombadori CML, Salutari V, Perri MT, Di Paola V, Rodolfino E, Scambia G, Manfredi R. Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. Korean J Radiol 2021;22:1310-22. [PMID: 34047505 DOI: 10.3348/kjr.2020.1299] [Reference Citation Analysis]
116 Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res 2016;22:2908-18. [PMID: 26787752 DOI: 10.1158/1078-0432.CCR-15-2412] [Cited by in Crossref: 318] [Cited by in F6Publishing: 200] [Article Influence: 53.0] [Reference Citation Analysis]
117 Chapman PB. Treating metastatic melanoma in 2014: what just happened and what is next? Am Soc Clin Oncol Educ Book 2014;:16-9. [PMID: 24857055 DOI: 10.14694/EdBook_AM.2014.34.16] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol 2014;8:1140-58. [PMID: 25178978 DOI: 10.1016/j.molonc.2014.07.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
119 Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 2016;34:4102-9. [PMID: 27863197 DOI: 10.1200/JCO.2016.67.2477] [Cited by in Crossref: 347] [Cited by in F6Publishing: 200] [Article Influence: 57.8] [Reference Citation Analysis]
120 Tran A, Sarosiek S, Ko NY. Challenges in the use of immunotherapy in metastatic melanoma. BMJ Case Rep 2016;2016:bcr2016216681. [PMID: 27864299 DOI: 10.1136/bcr-2016-216681] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
121 Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, Blanco E, Vera R, Kochan G, Escors D. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front Pharmacol 2020;11:441. [PMID: 32317979 DOI: 10.3389/fphar.2020.00441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
122 Kok PS, Cho D, Yoon WH, Ritchie G, Marschner I, Lord S, Friedlander M, Simes J, Lee CK. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e2011809. [PMID: 32897371 DOI: 10.1001/jamanetworkopen.2020.11809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
123 Hensley HH, Roder NA, O'Brien SW, Bickel LE, Xiao F, Litwin S, Connolly DC. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. Neoplasia 2012;14:451-62. [PMID: 22787427 DOI: 10.1596/neo.12480] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
124 Fortpied C, Vinches M. The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. Front Oncol 2019;9:634. [PMID: 31355146 DOI: 10.3389/fonc.2019.00634] [Reference Citation Analysis]
125 Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214-2219. [PMID: 25211661 DOI: 10.1038/bjc.2014.348] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
126 Wang ZX, Wu HX, Xie L, Lin WH, Liang F, Li J, Yang ZM, Xu RH. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. J Immunother Cancer 2021;9:e002114. [PMID: 33795385 DOI: 10.1136/jitc-2020-002114] [Reference Citation Analysis]
127 Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer 2016;4:64. [PMID: 27777773 DOI: 10.1186/s40425-016-0171-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
128 Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, Nishino M. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology 2020;297:87-96. [PMID: 32749204 DOI: 10.1148/radiol.2020200443] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
129 Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-931. [PMID: 22397654 DOI: 10.1056/nejmoa1112824] [Cited by in Crossref: 1315] [Cited by in F6Publishing: 722] [Article Influence: 131.5] [Reference Citation Analysis]
130 Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35-44. [PMID: 26997480 DOI: 10.1016/j.cell.2016.02.065] [Cited by in Crossref: 1279] [Cited by in F6Publishing: 1174] [Article Influence: 213.2] [Reference Citation Analysis]
131 Perez R, Moreno E, Garrido G, Crombet T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. Cancers (Basel) 2011;3:2014-31. [PMID: 24212794 DOI: 10.3390/cancers3022014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
132 Nakamoto R, Zaba LC, Rosenberg J, Reddy SA, Nobashi TW, Davidzon G, Aparici CM, Nguyen J, Moradi F, Iagaru A, Franc BL. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging 2020;47:2787-95. [PMID: 32296882 DOI: 10.1007/s00259-020-04792-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
133 Gamerith G, Auer T, Amann A, Putzer D, Schenk B, Kircher B, Hilbe W, Zwierzina H, Loeffler-Ragg J. Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. Cancer Biol Ther 2014;15:266-70. [PMID: 24351336 DOI: 10.4161/cbt.27327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
134 Calabrò L, Maio M. Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? Oncoimmunology 2014;3:e27482. [PMID: 24734215 DOI: 10.4161/onci.27482] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
135 Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011;17:3064-76. [PMID: 21558394 DOI: 10.1158/1078-0432.CCR-10-2234] [Cited by in Crossref: 85] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
136 De Wolf K, Kruse V, Sundahl N, van Gele M, Chevolet I, Speeckaert R, Brochez L, Ost P. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med 2017;15:21. [PMID: 28137295 DOI: 10.1186/s12967-017-1123-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
137 Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 2015;7:611-9. [PMID: 26098919 DOI: 10.2217/imt.15.35] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
138 Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther 2015;16:662-70. [PMID: 25806780 DOI: 10.1080/15384047.2015.1026507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
139 Zhang L, Wu L, Chen Q, Zhang B, Liu J, Liu S, Mo X, Li M, Chen Z, Chen L, You J, Jin Z, Chen X, Zhou Z, Zhang S. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine 2021;31:100673. [PMID: 33554079 DOI: 10.1016/j.eclinm.2020.100673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
140 Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Mol Diagn Ther 2021;25:409-24. [PMID: 33974235 DOI: 10.1007/s40291-021-00525-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res 2015;4:177-90. [PMID: 25870800 DOI: 10.3978/j.issn.2218-6751.2015.01.11] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
142 Wang M, Chen C, Jemielita T, Anderson J, Li XN, Hu C, Kang SP, Ibrahim N, Ebbinghaus S. Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma? J Immunother Cancer 2019;7:39. [PMID: 30736858 DOI: 10.1186/s40425-019-0513-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
143 Wendler A, Wehling M. Translatability scoring in drug development: eight case studies. J Transl Med 2012;10:39. [PMID: 22397594 DOI: 10.1186/1479-5876-10-39] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
144 Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247-1253. [PMID: 27485741 DOI: 10.1080/17425255.2016.1216976] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
145 Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res 2019;25:1709-17. [PMID: 30413527 DOI: 10.1158/1078-0432.CCR-18-2581] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 6.8] [Reference Citation Analysis]
146 Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 2013;119:3761-8. [PMID: 23922022 DOI: 10.1002/cncr.28290] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
147 Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget 2017;8:32918-29. [PMID: 28415633 DOI: 10.18632/oncotarget.16464] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
148 Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 2018;45:376-83. [PMID: 29124281 DOI: 10.1007/s00259-017-3870-6] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 17.2] [Reference Citation Analysis]
149 Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer 2021;9:e002597. [PMID: 34389617 DOI: 10.1136/jitc-2021-002597] [Reference Citation Analysis]
150 Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. J Natl Cancer Inst 2015;107:djv156. [PMID: 26113579 DOI: 10.1093/jnci/djv156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
151 Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386-396. [PMID: 25359635 DOI: 10.1007/s00259-014-2944-y] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
152 Blumenthal GM, Karuri SW, Zhang H, Zhang L, Khozin S, Kazandjian D, Tang S, Sridhara R, Keegan P, Pazdur R. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 2015;33:1008-14. [PMID: 25667291 DOI: 10.1200/JCO.2014.59.0489] [Cited by in Crossref: 116] [Cited by in F6Publishing: 62] [Article Influence: 16.6] [Reference Citation Analysis]
153 Tomasini P, Khobta N, Greillier L, Barlesi F. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol 2012;4:43-50. [PMID: 22423263 DOI: 10.1177/1758834011431718] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
154 Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol 2019;5:74-82. [PMID: 30242306 DOI: 10.1001/jamaoncol.2018.4224] [Cited by in Crossref: 234] [Cited by in F6Publishing: 224] [Article Influence: 78.0] [Reference Citation Analysis]
155 Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC. The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int 2015;6:S9-S44. [PMID: 25722939 DOI: 10.4103/2152-7806.151331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
156 Pennock GK, Chow LQ. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;20:812-822. [PMID: 26069281 DOI: 10.1634/theoncologist.2014-0422] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
157 Maksymiuk AW, Tappia PS, Bux RA, Moyer D, Huang G, Joubert P, Miller DW, Ramjiawan B, Sitar DS. Use of amantadine in the evaluation of response to chemotherapy in lung cancer: a pilot study. Future Sci OA 2021;7:FSO679. [PMID: 33815824 DOI: 10.2144/fsoa-2020-0176] [Reference Citation Analysis]
158 Yoshimura A, Takumi C, Tsuji T, Hamashima R, Shiotsu S, Yuba T, Urata Y, Hiraoka N. Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. Clin Case Rep. 2018;6:1338-1341. [PMID: 29988633 DOI: 10.1002/ccr3.1627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
159 Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 2011;29:3677-85. [PMID: 21825260 DOI: 10.1200/JCO.2010.34.5025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
160 Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41-53. [PMID: 23667165 DOI: 10.1189/jlb.1212631] [Cited by in Crossref: 206] [Cited by in F6Publishing: 192] [Article Influence: 22.9] [Reference Citation Analysis]
161 Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med 2014;7:357-65. [PMID: 25484597 DOI: 10.2147/PGPM.S53163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 1.1] [Reference Citation Analysis]
162 Tu MM, Ng TL, De Jong FC, Zuiverloon TCM, Fazzari FGT, Theodorescu D. Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. Bladder Cancer 2019;5:131-45. [PMID: 33365377 DOI: 10.3233/BLC-190218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
163 Lin M, Vanneste BGL, Yu Q, Chen Z, Peng J, Cai X. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review. Transl Lung Cancer Res 2021;10:3276-91. [PMID: 34430364 DOI: 10.21037/tlcr-21-575] [Reference Citation Analysis]
164 Zhao Q, Yu J, Meng X. A good start of immunotherapy in esophageal cancer. Cancer Med. 2019;8:4519-4526. [PMID: 31231980 DOI: 10.1002/cam4.2336] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
165 Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016;10:103-17. [PMID: 27536062 DOI: 10.2147/BTT.S87878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
166 Provencio M, Carcereny E, Artal Á. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clin Transl Oncol 2019;21:1464-71. [PMID: 30903517 DOI: 10.1007/s12094-019-02072-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Hid Cadena R, Abdulahad WH, Hospers GAP, Wind TT, Boots AMH, Heeringa P, Brouwer E. Checks and Balances in Autoimmune Vasculitis. Front Immunol 2018;9:315. [PMID: 29520282 DOI: 10.3389/fimmu.2018.00315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
168 Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J Immunother Cancer 2014;2:1. [PMID: 24829758 DOI: 10.1186/2051-1426-2-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
169 Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, Listì A, Cicero G, Rolfo C, Santini D, Russo A. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 2016;7:19738-47. [PMID: 26918451 DOI: 10.18632/oncotarget.7582] [Cited by in Crossref: 87] [Cited by in F6Publishing: 93] [Article Influence: 17.4] [Reference Citation Analysis]
170 Buder-Bakhaya K, Hassel JC. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. Front Immunol 2018;9:1474. [PMID: 30002656 DOI: 10.3389/fimmu.2018.01474] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 26.0] [Reference Citation Analysis]
171 Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs 2015;33:881-9. [PMID: 25924991 DOI: 10.1007/s10637-015-0243-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
172 Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy 2016;8:809-19. [PMID: 27349980 DOI: 10.2217/imt-2016-0001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
173 Wani SQ, Dar IA, Khan T, Lone MM, Afroz F. Radiation Therapy and its Effects Beyond the Primary Target: An Abscopal Effect. Cureus 2019;11:e4100. [PMID: 31057994 DOI: 10.7759/cureus.4100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
174 Hude I, Sasse S, Engert A, Bröckelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017;102:30-42. [PMID: 27884973 DOI: 10.3324/haematol.2016.150656] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
175 Gedye C, Hogg D, Butler M, Joshua AM. New treatments for metastatic melanoma. CMAJ 2014;186:754-60. [PMID: 24549129 DOI: 10.1503/cmaj.130989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
176 Spain L, Younger E, Hatipoglu E, Larkin J. Pembrolizumab in the management of metastatic melanoma. Melanoma Manag 2015;2:315-25. [PMID: 30190860 DOI: 10.2217/mmt.15.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
177 Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:75. [PMID: 30012210 DOI: 10.1186/s40425-018-0382-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 19.8] [Reference Citation Analysis]
178 Van Cutsem E, Verheul HM, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R, Seufferlein T. Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers (Basel). 2016;8. [PMID: 27589804 DOI: 10.3390/cancers8090081] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
179 Gao Y, Gao J, Mu G, Zhang Y, Huang F, Zhang W, Ren C, Yang C, Liu J. Selectively enhancing radiosensitivity of cancer cells via in situ enzyme-instructed peptide self-assembly. Acta Pharm Sin B 2020;10:2374-83. [PMID: 33354508 DOI: 10.1016/j.apsb.2020.07.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016;34:2619-2626. [PMID: 27298410 DOI: 10.1200/jco.2016.67.1529] [Cited by in Crossref: 308] [Cited by in F6Publishing: 181] [Article Influence: 51.3] [Reference Citation Analysis]
181 Persigehl T, Poeppel TD, Sedlaczek O. [Radiological response assessment of modern immunotherapy using iRECIST]. Radiologe 2017;57:826-33. [PMID: 28812098 DOI: 10.1007/s00117-017-0289-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
182 Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273-290. [PMID: 26977780 DOI: 10.1038/nrclinonc.2016.25] [Cited by in Crossref: 544] [Cited by in F6Publishing: 503] [Article Influence: 90.7] [Reference Citation Analysis]
183 Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020;26:5129-5139. [PMID: 32591464 DOI: 10.1158/1078-0432.ccr-20-1025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
184 Xiao Z, Puré E. Imaging of T-cell Responses in the Context of Cancer Immunotherapy. Cancer Immunol Res 2021;9:490-502. [PMID: 33941536 DOI: 10.1158/2326-6066.CIR-20-0678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Lepir T, Zaghouani M, Roche SP, Li YY, Suarez M, Irias MJ, Savaraj N. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report. Medicine (Baltimore) 2019;98:e13804. [PMID: 30633154 DOI: 10.1097/MD.0000000000013804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
186 Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29:489-498. [PMID: 20082117 DOI: 10.1007/s10637-009-9376-8] [Cited by in Crossref: 207] [Cited by in F6Publishing: 188] [Article Influence: 17.3] [Reference Citation Analysis]
187 Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist 2019;24:820-8. [PMID: 30867242 DOI: 10.1634/theoncologist.2018-0433] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
188 Gibson E, Koblbauer I, Begum N, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M. Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. Pharmacoeconomics 2017;35:1257-70. [PMID: 28866758 DOI: 10.1007/s40273-017-0558-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
189 Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol 2015;6:33. [PMID: 25755649 DOI: 10.3389/fneur.2015.00033] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 14.6] [Reference Citation Analysis]
190 Gerwing M, Krähling T, Schliemann C, Harrach S, Schwöppe C, Berdel AF, Klein S, Hartmann W, Wardelmann E, Heindel WL, Lenz G, Berdel WE, Wildgruber M. Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease. Cancers (Basel) 2021;13:5880. [PMID: 34884988 DOI: 10.3390/cancers13235880] [Reference Citation Analysis]
191 Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655-668. [PMID: 28653677 DOI: 10.1038/nrclinonc.2017.88] [Cited by in Crossref: 373] [Cited by in F6Publishing: 350] [Article Influence: 74.6] [Reference Citation Analysis]
192 de la Cruz-Merino L, Barco-Sánchez A, Henao Carrasco F, Nogales Fernández E, Vallejo Benítez A, Brugal Molina J, Martínez Peinado A, Grueso López A, Ruiz Borrego M, Codes Manuel de Villena M, Sánchez-Margalet V, Nieto-García A, Alba Conejo E, Casares Lagar N, Ibáñez Martínez J. New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013;2013:785317. [PMID: 23861693 DOI: 10.1155/2013/785317] [Cited by in Crossref: 31] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
193 Nishino M, Hatabu H, Hodi FS. Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.Radiology. 2019;290:9-22. [PMID: 30457485 DOI: 10.1148/radiol.2018181349] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 17.3] [Reference Citation Analysis]
194 Facchinetti F, Bordi P, Leonetti A, Buti S, Tiseo M. Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Des Devel Ther 2018;12:2857-73. [PMID: 30237696 DOI: 10.2147/DDDT.S124380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
195 Cooper AJ, Carlino MS, Kefford RF. Immune checkpoint inhibitors in melanoma. Melanoma Manag 2015;2:267-84. [PMID: 30190854 DOI: 10.2217/mmt.15.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
196 Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol 2014;7:58. [PMID: 25355407 DOI: 10.1186/s13045-014-0058-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
197 Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. Imaging Biomarkers in Immunotherapy. Biomark Cancer 2016;8:1-13. [PMID: 26949344 DOI: 10.4137/BIC.S31805] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
198 Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res 2013;55:22-33. [PMID: 22941561 DOI: 10.1007/s12026-012-8346-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
199 Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, Casagrande M, Ongaro E, Berretta M, Avallone A, Rosati G, Giuliani F, Fasola G. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget 2015;6:28716-30. [PMID: 26308250 DOI: 10.18632/oncotarget.4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
200 Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kämpgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, Assi Z, Garbe C, Schadendorf D. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med 2015;13:351. [PMID: 26541511 DOI: 10.1186/s12967-015-0716-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
201 Zakaria R, Radon M, Mills S, Mitchell D, Palmieri C, Chung C, Jenkinson MD. The Role of the Immune Response in Brain Metastases: Novel Imaging Biomarkers for Immunotherapy. Front Oncol 2021;11:711405. [PMID: 34765539 DOI: 10.3389/fonc.2021.711405] [Reference Citation Analysis]
202 Melian M, Lorente D, Aparici F, Juan O. Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment. Thorac Cancer 2018;9:1770-3. [PMID: 30276979 DOI: 10.1111/1759-7714.12873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
203 Zhang S, Ren S. [Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application]. Zhongguo Fei Ai Za Zhi 2017;20:645-51. [PMID: 28935020 DOI: 10.3779/j.issn.1009-3419.2017.09.10] [Reference Citation Analysis]
204 Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? World J Radiol 2017; 9(2): 27-33 [PMID: 28298962 DOI: 10.4329/wjr.v9.i2.27] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
205 Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U. The dark side of immunotherapy. Ann Transl Med 2021;9:1041. [PMID: 34277841 DOI: 10.21037/atm-20-4750] [Reference Citation Analysis]
206 Mansfield AS, Peikert T, Vogelzang NJ, Symanowski JT. Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clin Proc 2018;93:1026-33. [PMID: 29804728 DOI: 10.1016/j.mayocp.2018.01.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Galldiks N, Kocher M, Ceccon G, Werner JM, Brunn A, Deckert M, Pope WB, Soffietti R, Le Rhun E, Weller M, Tonn JC, Fink GR, Langen KJ. Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro Oncol 2020;22:17-30. [PMID: 31437274 DOI: 10.1093/neuonc/noz147] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 30.0] [Reference Citation Analysis]
208 Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17:1374-85. [PMID: 27592805 DOI: 10.1016/S1470-2045(16)30364-3] [Cited by in Crossref: 717] [Cited by in F6Publishing: 376] [Article Influence: 119.5] [Reference Citation Analysis]
209 Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325. [PMID: 25506582 DOI: 10.3389/fonc.2014.00325] [Cited by in Crossref: 139] [Cited by in F6Publishing: 138] [Article Influence: 17.4] [Reference Citation Analysis]
210 Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 2016;16:121-6. [PMID: 26822578 DOI: 10.1038/nrc.2016.2] [Cited by in Crossref: 217] [Cited by in F6Publishing: 210] [Article Influence: 36.2] [Reference Citation Analysis]
211 Danylesko I, Shouval R, Shem-Tov N, Yerushalmi R, Jacoby E, Besser MJ, Shimoni A, Davidson T, Beider K, Mevorach D, Fried S, Nagler A, Avigdor A. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant 2021;56:1134-43. [PMID: 33268830 DOI: 10.1038/s41409-020-01156-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
212 Nguyen A, Ramesh A, Kumar S, Nandi D, Brouillard A, Wells A, Pobezinsky L, Osborne B, Kulkarni AA. Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Sci Adv 2020;6:eabc2777. [PMID: 33008894 DOI: 10.1126/sciadv.abc2777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520. [PMID: 26028255 DOI: 10.1056/nejmoa1500596] [Cited by in Crossref: 4650] [Cited by in F6Publishing: 2768] [Article Influence: 664.3] [Reference Citation Analysis]
214 Ascierto PA. Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR. Melanoma Management 2015;2:9-14. [DOI: 10.2217/mmt.14.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
215 Jarkowski A 3rd, Khushalani NI. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog 2014;13:1. [PMID: 24737949 DOI: 10.4103/1477-3163.126759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
216 Leven C, Padelli M, Carré JL, Bellissant E, Misery L. Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. Clin Pharmacokinet 2019;58:1393-405. [PMID: 31183812 DOI: 10.1007/s40262-019-00789-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
217 Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. J Immunother Cancer 2017;5:83. [PMID: 29157311 DOI: 10.1186/s40425-017-0290-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
218 Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C, Ammari S. Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother 2021;70:221-32. [PMID: 32700090 DOI: 10.1007/s00262-020-02647-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
219 Mardiana S, Gill S. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol 2020;10:697. [PMID: 32435621 DOI: 10.3389/fonc.2020.00697] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
220 De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, Buonadonna A, Zagonel V, Cecchin E, Innocenti F, Toffoli G. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One 2014;9:e84940. [PMID: 24497922 DOI: 10.1371/journal.pone.0084940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
221 Liu J, Lin HS, Hou W, Hua BJ, Zhang PT, Li J, Wang SY, Xie Y, Zhang Y, Xie GR, Zhang MY, Shi WG, Guan NB, Guan TY, Li CH, Lu LY, Zhang Y, Li DR, Liu H. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. Chin J Integr Med 2017;23:733-9. [PMID: 27796823 DOI: 10.1007/s11655-016-2737-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
222 Longoria TC, Tewari KS. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations. Drugs 2015;75:1853-65. [PMID: 26474780 DOI: 10.1007/s40265-015-0481-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
223 Cuccarini V, Aquino D, Gioppo A, Anghileri E, Pellegatta S, Schettino C, Mazzi F, Finocchiaro G, Bruzzone MG, Eoli M. Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. J Clin Med 2019;8:E2007. [PMID: 31744235 DOI: 10.3390/jcm8112007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
224 Teulings HE, Tjin EPM, Willemsen KJ, van der Kleij S, Ter Meulen S, Kemp EH, Krebbers G, van Noesel CJM, Franken CLMC, Drijfhout JW, Melief CJM, Nieuweboer-Krobotova L, Nieweg OE, van der Hage JA, van der Veen JPW, Relyveld GN, Luiten RM. Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial. Oncoimmunology 2018;7:e1419113. [PMID: 29632737 DOI: 10.1080/2162402X.2017.1419113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
225 Balatoni T, Ladányi A, Fröhlich G, Czirbesz K, Kovács P, Pánczél G, Bence E, Plótár V, Liszkay G. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Pathol Oncol Res 2020;26:317-25. [PMID: 30225783 DOI: 10.1007/s12253-018-0466-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
226 Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014;63:1769-1781. [PMID: 24555999 DOI: 10.1136/gutjnl-2013-306271] [Cited by in Crossref: 172] [Cited by in F6Publishing: 167] [Article Influence: 21.5] [Reference Citation Analysis]
227 Colloca GA, Venturino A, Guarneri D. Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer. Int J Clin Oncol 2019;24:1406-11. [PMID: 31289956 DOI: 10.1007/s10147-019-01504-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Wilgenhof S, Du Four S, Everaert H, Neyns B. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports. Cancer Invest 2012;30:712-20. [PMID: 23043499 DOI: 10.3109/07357907.2012.727934] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
229 Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 2018;115:2467-72. [PMID: 29453278 DOI: 10.1073/pnas.1719264115] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 16.0] [Reference Citation Analysis]
230 Sherrill B, Wang J, Kotapati S, Chin K. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer. 2013;109:8-13. [PMID: 23787916 DOI: 10.1038/bjc.2013.298] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
231 Liu J, Blake SJ, Smyth MJ, Teng MW. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology 2014;3:e22. [PMID: 25505970 DOI: 10.1038/cti.2014.18] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
232 Oppel-Heuchel H, Grimm MO. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]. Urologe A 2016;55:677-90. [PMID: 27146870 DOI: 10.1007/s00120-016-0109-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
233 Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011;5:489-95. [PMID: 22267918 DOI: 10.2147/DDDT.S10945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
234 Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer 2018;6:129. [PMID: 30470260 DOI: 10.1186/s40425-018-0447-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
235 McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Qual Life Res 2019;28:109-19. [PMID: 30191365 DOI: 10.1007/s11136-018-1984-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
236 Gerber NK, Young RJ, Barker CA, Wolchok JD, Chan TA, Yamada Y, Friguglietti L, Beal K. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. J Neurooncol 2015;121:159-65. [PMID: 25273687 DOI: 10.1007/s11060-014-1617-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
237 Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, Ammari S, Soria JC. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2014;20:246-52. [PMID: 24240109 DOI: 10.1158/1078-0432.CCR-13-2098] [Cited by in Crossref: 86] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
238 Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res. 2010;16:4057-4065. [PMID: 20647477 DOI: 10.1158/1078-0432.ccr-10-1093] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
239 Manlove LS, Schenkel JM, Manlove KR, Pauken KE, Williams RT, Vezys V, Farrar MA. Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J Immunol 2016;196:4793-804. [PMID: 27183622 DOI: 10.4049/jimmunol.1600130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
240 Baxevanis CN, Fortis SP, Ardavanis A, Perez SA. Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. Cancers (Basel) 2020;12:E2908. [PMID: 33050520 DOI: 10.3390/cancers12102908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
241 Xu H, Cao X. Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. Front Med 2011;5:323-32. [PMID: 22198743 DOI: 10.1007/s11684-011-0172-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
242 Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitiis F, Marchetti P, Amato G. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015;112:1904-1910. [PMID: 26010413 DOI: 10.1038/bjc.2015.180] [Cited by in Crossref: 137] [Cited by in F6Publishing: 136] [Article Influence: 19.6] [Reference Citation Analysis]
243 Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B. Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. J Oncol 2019;2019:5269062. [PMID: 31182961 DOI: 10.1155/2019/5269062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
244 Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, Kim C, Chernyak V, Yokoo T, Meyer J, Newton I, Do RK. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY). 2018;43:218-230. [PMID: 28780679 DOI: 10.1007/s00261-017-1281-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 17.7] [Reference Citation Analysis]
245 Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33:1974-1982. [PMID: 25605845 DOI: 10.1200/jco.2014.59.4358] [Cited by in Crossref: 1392] [Cited by in F6Publishing: 826] [Article Influence: 198.9] [Reference Citation Analysis]
246 Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 2016;43:1792-801. [PMID: 27072811 DOI: 10.1007/s00259-016-3365-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
247 MacDiarmid JA, Langova V, Bailey D, Pattison ST, Pattison SL, Christensen N, Armstrong LR, Brahmbhatt VN, Smolarczyk K, Harrison MT, Costa M, Mugridge NB, Sedliarou I, Grimes NA, Kiss DL, Stillman B, Hann CL, Gallia GL, Graham RM, Brahmbhatt H. Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. PLoS One 2016;11:e0151832. [PMID: 27050167 DOI: 10.1371/journal.pone.0151832] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
248 Kyi C, Roudko V, Sabado R, Saenger Y, Loging W, Mandeli J, Thin TH, Lehrer D, Donovan M, Posner M, Misiukiewicz K, Greenbaum B, Salazar A, Friedlander P, Bhardwaj N. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. Clin Cancer Res 2018;24:4937-48. [PMID: 29950349 DOI: 10.1158/1078-0432.CCR-17-1866] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
249 Wilkie KP, Hahnfeldt P. Modeling the Dichotomy of the Immune Response to Cancer: Cytotoxic Effects and Tumor-Promoting Inflammation. Bull Math Biol 2017;79:1426-48. [PMID: 28585066 DOI: 10.1007/s11538-017-0291-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
250 Chew GL, Campbell AE, De Neef E, Sutliff NA, Shadle SC, Tapscott SJ, Bradley RK. DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade. Dev Cell 2019;50:658-671.e7. [PMID: 31327741 DOI: 10.1016/j.devcel.2019.06.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
251 van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. BMJ Open 2020;10:e044036. [PMID: 33234662 DOI: 10.1136/bmjopen-2020-044036] [Reference Citation Analysis]
252 Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 2018;50:1271-81. [PMID: 30150660 DOI: 10.1038/s41588-018-0200-2] [Cited by in Crossref: 187] [Cited by in F6Publishing: 164] [Article Influence: 46.8] [Reference Citation Analysis]
253 Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6:19976-19989. [PMID: 26280277 DOI: 10.18632/oncotarget.5116] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 10.2] [Reference Citation Analysis]
254 Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C. Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma. Clinicoecon Outcomes Res 2020;12:241-52. [PMID: 32440174 DOI: 10.2147/CEOR.S238725] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
255 Lim I, Lindenberg ML, Mena E, Verdini N, Shih JH, Mayfield C, Thompson R, Lin J, Vega A, Mallek M, Cadena J, Diaz C, Mortazavi A, Knopp M, Wright C, Stein M, Pal S, Choyke PL, Apolo AB. 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. Eur J Nucl Med Mol Imaging 2020;47:178-84. [PMID: 31522271 DOI: 10.1007/s00259-019-04483-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
256 Linck RDM, Costa RLP, Garicochea B. Cancer immunology and melanoma immunotherapy. An Bras Dermatol 2017;92:830-5. [PMID: 29364441 DOI: 10.1590/abd1806-4841.201756511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
257 Trommer-Nestler M, Marnitz S, Kocher M, Rueß D, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Jablonska K, Celik E, Ruge MI, Baues C. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. Int J Mol Sci 2018;19:E2653. [PMID: 30205431 DOI: 10.3390/ijms19092653] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
258 Page DB, Postow MA, Callahan MK, Wolchok JD. Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013;15:500-8. [PMID: 23933888 DOI: 10.1007/s11912-013-0337-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
259 Rivalland G, Scott AM, John T. Standard of care in immunotherapy trials: Challenges and considerations. Hum Vaccin Immunother 2017;13:2164-78. [PMID: 28267397 DOI: 10.1080/21645515.2016.1277845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
260 Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer 2018;6:44. [PMID: 29848375 DOI: 10.1186/s40425-018-0362-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
261 Karlsson AK, Saleh SN. Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clin Cosmet Investig Dermatol 2017;10:325-39. [PMID: 28883738 DOI: 10.2147/CCID.S120877] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 7.4] [Reference Citation Analysis]
262 Lim AM, Cavanagh K, Hicks RJ, McLean L, Goh MS, Webb A, Rischin D. Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. Front Oncol 2021;11:656611. [PMID: 33937066 DOI: 10.3389/fonc.2021.656611] [Reference Citation Analysis]
263 Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
264 Zhang D, Li Y, Li H, Tang T, Zheng Y, Guo X, Xu X. A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer. Cancer Manag Res 2021;13:7131-7. [PMID: 34531687 DOI: 10.2147/CMAR.S314369] [Reference Citation Analysis]
265 Wang W, Gao Z, Wang L, Li J, Yu J, Han S, Meng X. Application and Prospects of Molecular Imaging in Immunotherapy. Cancer Manag Res 2020;12:9389-403. [PMID: 33061627 DOI: 10.2147/CMAR.S269773] [Reference Citation Analysis]
266 Zhu GL, Yang KB, Tang SQ, Peng L. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. Cancer Med 2021;10:8272-87. [PMID: 34668660 DOI: 10.1002/cam4.4347] [Reference Citation Analysis]
267 du Rusquec P, Le Tourneau C. Drug Development in Tissue-Agnostic Indications. Cancers (Basel) 2021;13:2758. [PMID: 34199382 DOI: 10.3390/cancers13112758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013;258:879-886. [PMID: 23657083 DOI: 10.1097/sla.0b013e318292919e] [Cited by in Crossref: 80] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
269 Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013;119:3687-95. [PMID: 23913718 DOI: 10.1002/cncr.28282] [Cited by in Crossref: 134] [Cited by in F6Publishing: 119] [Article Influence: 14.9] [Reference Citation Analysis]
270 Harshman LC, Choueiri TK, Drake C, Stephen Hodi F Jr. Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014;20:272-80. [PMID: 25098288 DOI: 10.1097/PPO.0000000000000055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
271 Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight 2016;1:e86014. [PMID: 27182556 DOI: 10.1172/jci.insight.86014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
272 Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534-42. [PMID: 26545842 DOI: 10.1016/S1470-2045(15)00088-1] [Cited by in Crossref: 359] [Cited by in F6Publishing: 194] [Article Influence: 59.8] [Reference Citation Analysis]
273 Rashid AS, Venigalla S, Dzeda M, Masters GA. A Case Report of the Clinico-radiologic Challenges of Assessing Treatment Response after Stereotactic Radiation of Oligometastases Preceded by Immunotherapy: Pseudoprogression, Mixed Response Patterns, and Opportunities for Precision Radiation. Cureus 2019;11:e4264. [PMID: 31139523 DOI: 10.7759/cureus.4264] [Reference Citation Analysis]
274 Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265. [PMID: 27979383 DOI: 10.1016/s0140-6736(16)32517-x] [Cited by in Crossref: 2108] [Cited by in F6Publishing: 1291] [Article Influence: 351.3] [Reference Citation Analysis]
275 Lopez-Obregon B, Barreto MP, Fyfe A, McKinnon G, Webb C, Temple-Oberle C. Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'évaluation de l'interleukine-2 intralésionnelle pour traiter les mélanomes en transit. Plast Surg (Oakv) 2021;29:4-9. [PMID: 33614534 DOI: 10.1177/2292550320936669] [Reference Citation Analysis]
276 Rossfeld K, Hade EM, Gangi A, Perez M, Kinsey EN, Grabska J, Ederle A, Zager J, Salama AK, Olencki TE, Beasley GM. Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. Int J Surg Oncol (N Y) 2017;2:e43. [PMID: 29177235 DOI: 10.1097/IJ9.0000000000000043] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
277 Sato Y, Morimoto T, Hara S, Nagata K, Hosoya K, Nakagawa A, Tachikawa R, Tomii K. Dissociated response and clinical benefit in patients treated with nivolumab monotherapy. Invest New Drugs 2021;39:1170-8. [PMID: 33566254 DOI: 10.1007/s10637-021-01077-7] [Reference Citation Analysis]
278 Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res 2019;25:2174-84. [PMID: 30670497 DOI: 10.1158/1078-0432.CCR-18-3206] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
279 Wang DY, Johnson DB. Advances in the development of intralesional therapies for melanoma. Melanoma Manag 2016;3:259-66. [PMID: 30190897 DOI: 10.2217/mmt-2016-0020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
280 Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015;33:1430-7. [PMID: 25452452 DOI: 10.1200/JCO.2014.59.0703] [Cited by in Crossref: 638] [Cited by in F6Publishing: 359] [Article Influence: 79.8] [Reference Citation Analysis]
281 Zhang C, Zhong W. [Graphic Evolution Witness the Development of Lung Cancer Translational Research]. Zhongguo Fei Ai Za Zhi 2016;19:403-8. [PMID: 27335306 DOI: 10.3779/j.issn.1009-3419.2016.06.21] [Reference Citation Analysis]
282 Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET. Theranostics 2020;10:925-37. [PMID: 31903160 DOI: 10.7150/thno.35989] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
283 Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med 2021;11:355. [PMID: 33946635 DOI: 10.3390/jpm11050355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
284 Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clin Cancer Res 2017;23:4959-69. [PMID: 28864724 DOI: 10.1158/1078-0432.CCR-16-3065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
285 Kas B, Talbot H, Ferrara R, Richard C, Lamarque JP, Pitre-Champagnat S, Planchard D, Balleyguier C, Besse B, Mezquita L, Lassau N, Caramella C. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. JAMA Oncol. 2020;6:1039-1046. [PMID: 32525513 DOI: 10.1001/jamaoncol.2020.1634] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 24.0] [Reference Citation Analysis]
286 Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol Med 2019;11:e10293. [PMID: 31273938 DOI: 10.15252/emmm.201910293] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
287 Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, Kato Y, Yamamoto K, Uemura H, Suzuki Y, Murata S, Ohashi K. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci Rep 2017;7:8951. [PMID: 28827658 DOI: 10.1038/s41598-017-09444-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
288 Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther 2014;22:18-27. [PMID: 24048441 DOI: 10.1038/mt.2013.219] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
289 Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 2015;7:181-91. [PMID: 26673806 DOI: 10.1177/1758834015572284] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
290 Tsui JM, Mihalcioiu C, Cury FL. Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. Cureus 2018;10:e2238. [PMID: 29719740 DOI: 10.7759/cureus.2238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
291 Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics (Basel) 2021;11:1041. [PMID: 34198874 DOI: 10.3390/diagnostics11061041] [Reference Citation Analysis]
292 Uhrig M, Sedlmair M, Schlemmer HP, Hassel JC, Ganten M. Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. Cancer Imaging 2013;13:306-13. [PMID: 23876444 DOI: 10.1102/1470-7330.2013.0031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
293 Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M. Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. Onco Targets Ther 2015;8:1149-56. [PMID: 26045669 DOI: 10.2147/OTT.S82624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
294 Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, Lotem M, Agur Z. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Transl Med 2019;17:338. [PMID: 31590677 DOI: 10.1186/s12967-019-2081-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
295 Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol 2018;25:e373-84. [PMID: 30464687 DOI: 10.3747/co.25.3840] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
296 Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res 2015;3:986-91. [PMID: 25943535 DOI: 10.1158/2326-6066.CIR-15-0066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
297 El-Osta H, Shahid K, Mills GM, Peddi P. Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016;9:5101-16. [PMID: 27574451 DOI: 10.2147/OTT.S111209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
298 Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428-1439. [PMID: 29584546 DOI: 10.1200/jco.2017.76.0793] [Cited by in Crossref: 285] [Cited by in F6Publishing: 143] [Article Influence: 71.3] [Reference Citation Analysis]
299 Zeltsman M, Mayor M, Jones DR, Adusumilli PS. Surgical immune interventions for solid malignancies. Am J Surg 2016;212:682-690.e5. [PMID: 27659157 DOI: 10.1016/j.amjsurg.2016.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
300 Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020;8:e000347. [PMID: 32188704 DOI: 10.1136/jitc-2019-000347] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 31.0] [Reference Citation Analysis]
301 Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep 2018;8:2592. [PMID: 29416054 DOI: 10.1038/s41598-018-19245-w] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
302 Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010;8:38. [PMID: 20406483 DOI: 10.1186/1479-5876-8-38] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
303 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019;30:582-8. [PMID: 30715153 DOI: 10.1093/annonc/mdz011] [Cited by in Crossref: 228] [Cited by in F6Publishing: 214] [Article Influence: 114.0] [Reference Citation Analysis]
304 Vrankar M, Unk M. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiol Oncol 2018;52:365-9. [PMID: 30367809 DOI: 10.2478/raon-2018-0037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
305 Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res 2019;25:524-32. [PMID: 30420448 DOI: 10.1158/1078-0432.CCR-18-2258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
306 Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes MB, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood 2017;130:1713-21. [PMID: 28830889 DOI: 10.1182/blood-2017-04-780155] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 19.0] [Reference Citation Analysis]
307 Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015;112:6140-6145. [PMID: 25918390 DOI: 10.1073/pnas.1417320112] [Cited by in Crossref: 344] [Cited by in F6Publishing: 315] [Article Influence: 49.1] [Reference Citation Analysis]
308 Arasanz H, Zuazo M, Bocanegra A, Gato M, Martínez-Aguillo M, Morilla I, Fernández G, Hernández B, López P, Alberdi N, Hernández C, Chocarro L, Teijeira L, Vera R, Kochan G, Escors D. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers (Basel) 2020;12:E344. [PMID: 32033028 DOI: 10.3390/cancers12020344] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
309 Morbelli S, Calcagni ML, Cistaro A, Farsad M, Guerra L, Nanni C, Bianchi A. The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC). Clin Transl Imaging 2020;8:29-38. [DOI: 10.1007/s40336-019-00354-z] [Reference Citation Analysis]
310 Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010;37:473-84. [PMID: 21074063 DOI: 10.1053/j.seminoncol.2010.09.001] [Cited by in Crossref: 158] [Cited by in F6Publishing: 149] [Article Influence: 13.2] [Reference Citation Analysis]
311 Cella D, Grünwald V, Nathan P, Doan J, Dastani H, Taylor F, Bennett B, DeRosa M, Berry S, Broglio K, Berghorn E, Motzer RJ. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:994-1003. [PMID: 27283863 DOI: 10.1016/S1470-2045(16)30125-5] [Cited by in Crossref: 149] [Cited by in F6Publishing: 63] [Article Influence: 24.8] [Reference Citation Analysis]
312 Maitland ML, Wilkerson J, Karovic S, Zhao B, Flynn J, Zhou M, Hilden P, Ahmed FS, Dercle L, Moskowitz CS, Tang Y, Connors DE, Adam SJ, Kelloff G, Gonen M, Fojo T, Schwartz LH, Oxnard GR. Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clin Cancer Res 2020;26:6464-74. [PMID: 32988968 DOI: 10.1158/1078-0432.CCR-20-1493] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
313 Lipson EJ. Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology. 2013;2:e23661. [PMID: 23734322 DOI: 10.4161/onci.23661] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
314 Khattak M, Fisher R, Turajlic S, Larkin J. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol 2013;5:105-18. [PMID: 23450149 DOI: 10.1177/1758834012466280] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
315 Maccalli C, Giannarelli D, Chiarucci C, Cutaia O, Giacobini G, Hendrickx W, Amato G, Annesi D, Bedognetti D, Altomonte M, Danielli R, Calabrò L, Di Giacomo AM, Marincola FM, Parmiani G, Maio M. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. Oncoimmunology 2017;6:e1323618. [PMID: 28811958 DOI: 10.1080/2162402X.2017.1323618] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
316 Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer 2020;8:e000146. [PMID: 32107275 DOI: 10.1136/jitc-2019-000146] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
317 Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC, Motzer RJ. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol 2020;38:1154-63. [PMID: 31961766 DOI: 10.1200/JCO.19.01598] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 39.0] [Reference Citation Analysis]
318 Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, Assanah EO, Davies R, Espat NJ, Junghans RP. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res. 2015;21:3149-3159. [PMID: 25850950 DOI: 10.1158/1078-0432.ccr-14-1421] [Cited by in Crossref: 199] [Cited by in F6Publishing: 123] [Article Influence: 28.4] [Reference Citation Analysis]
319 Mathios D, Srivastava S, Kim T, Bettegowda C, Lim M. Emerging Technologies for Non-invasive Monitoring of Treatment Response to Immunotherapy for Brain Tumors. Neuromolecular Med 2021. [PMID: 34297308 DOI: 10.1007/s12017-021-08677-9] [Reference Citation Analysis]
320 Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, Grimaldi AM, Pinto A, Ascierto PA. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med 2017;15:244. [PMID: 29202855 DOI: 10.1186/s12967-017-1348-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
321 Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013;1:92-8. [PMID: 24777500 DOI: 10.1158/2326-6066.CIR-13-0082] [Cited by in Crossref: 108] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
322 Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33:2004-2012. [PMID: 25897158 DOI: 10.1200/jco.2014.58.3708] [Cited by in Crossref: 740] [Cited by in F6Publishing: 438] [Article Influence: 105.7] [Reference Citation Analysis]
323 Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:85-96. [PMID: 25755681 DOI: 10.1177/1758834014567470] [Cited by in Crossref: 135] [Cited by in F6Publishing: 124] [Article Influence: 19.3] [Reference Citation Analysis]
324 Yirgin IK, Erturk SM, Dogan I, Vatansever S. Are radiologists ready to evaluate true response to immunotherapy? Insights Imaging 2021;12:29. [PMID: 33625595 DOI: 10.1186/s13244-021-00968-w] [Reference Citation Analysis]
325 Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer 2017;5:22. [PMID: 28344808 DOI: 10.1186/s40425-017-0222-9] [Cited by in Crossref: 98] [Cited by in F6Publishing: 98] [Article Influence: 19.6] [Reference Citation Analysis]
326 Trefzer U, Gutzmer R, Wilhelm T, Schenck F, Kähler KC, Jacobi V, Witthohn K, Lentzen H, Mohr P. Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. J Immunother Cancer 2014;2:27. [PMID: 25324973 DOI: 10.1186/s40425-014-0027-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
327 Zhao L, Ma B, Yang Y, Li T, Han L, Gao Q. Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. Front Oncol 2020;10:507. [PMID: 32373522 DOI: 10.3389/fonc.2020.00507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
328 Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med 2016;14:20. [PMID: 26850630 DOI: 10.1186/s12916-016-0571-0] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 12.7] [Reference Citation Analysis]
329 Szturz P, Vermorken JB. Immunotherapy in head and neck cancer: aiming at EXTREME precision. BMC Med 2017;15:110. [PMID: 28571578 DOI: 10.1186/s12916-017-0879-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
330 Menis J, Litière S, Tryfonidis K, Golfinopoulos V. The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med 2016;4:267. [PMID: 27563654 DOI: 10.21037/atm.2016.06.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
331 Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer. 2013;108:1560-1565. [PMID: 23511566 DOI: 10.1038/bjc.2013.117] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 10.8] [Reference Citation Analysis]
332 Hodi FS, Wolchok JD. Reply to M. Nishino. J Clin Oncol 2016;34:3481. [PMID: 27458281 DOI: 10.1200/JCO.2016.69.1097] [Reference Citation Analysis]
333 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-489. [PMID: 22193102 DOI: 10.1038/nature10673] [Cited by in Crossref: 2030] [Cited by in F6Publishing: 1895] [Article Influence: 184.5] [Reference Citation Analysis]
334 Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. Cancer Manag Res 2012;4:1-8. [PMID: 22346364 DOI: 10.2147/CMAR.S15551] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
335 Nishino M, Hong F, Ricciuti B, Hatabu H, Awad MM. Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250409 DOI: 10.1200/PO.20.00478] [Reference Citation Analysis]
336 Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2015;64:459-65. [PMID: 25603775 DOI: 10.1007/s00262-014-1652-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
337 Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front Oncol 2013;3:275. [PMID: 24273748 DOI: 10.3389/fonc.2013.00275] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
338 Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H. Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Rev Neurother 2021;21:205-19. [PMID: 33225764 DOI: 10.1080/14737175.2020.1855144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
339 Liu K, Qin Z, Xu X, Li T, Ge Y, Mao H, Xing C. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis. Front Oncol 2021;11:662731. [PMID: 34221977 DOI: 10.3389/fonc.2021.662731] [Reference Citation Analysis]
340 Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 2014;6:279-89. [PMID: 25018651 DOI: 10.2147/CMAR.S64979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
341 Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis 2018;10:S1564-80. [PMID: 29951307 DOI: 10.21037/jtd.2018.01.131] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
342 Shah R, Botteman M, Solem CT, Luo L, Doan J, Cella D, Motzer RJ. A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC).Clin Genitourin Cancer. 2019;17:356-365.e1. [PMID: 31272883 DOI: 10.1016/j.clgc.2019.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
343 Guo W. [Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer]. Hua Xi Kou Qiang Yi Xue Za Zhi 2020;38:489-94. [PMID: 33085230 DOI: 10.7518/hxkq.2020.05.003] [Reference Citation Analysis]
344 Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 2017;18:42-51. [PMID: 27932068 DOI: 10.1016/S1470-2045(16)30565-4] [Cited by in Crossref: 257] [Cited by in F6Publishing: 150] [Article Influence: 42.8] [Reference Citation Analysis]
345 Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, Wang LJ, Armenio V, Espat NJ, Junghans RP. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther 2020;27:341-55. [PMID: 31155611 DOI: 10.1038/s41417-019-0104-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
346 Wu MP, Reinshagen KL, Cunnane MB, Shalhout SZ, Kaufman HL, Miller D, Emerick KS. Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma. Laryngoscope 2021. [PMID: 34797598 DOI: 10.1002/lary.29953] [Reference Citation Analysis]
347 Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011;239:27-44. [PMID: 21198663 DOI: 10.1111/j.1600-065X.2010.00979.x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 118] [Article Influence: 17.8] [Reference Citation Analysis]
348 Mählmann K, Feige K, Juhls C, Endmann A, Schuberth HJ, Oswald D, Hellige M, Doherr M, Cavalleri JM. Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. BMC Vet Res 2015;11:132. [PMID: 26063232 DOI: 10.1186/s12917-015-0422-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
349 Junghans RP. The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther 2017;24:89-99. [PMID: 28392558 DOI: 10.1038/cgt.2016.82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
350 Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011;31:813-28. [PMID: 21923608 DOI: 10.1592/phco.31.8.813] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
351 Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci 2016;107:107-15. [PMID: 26678880 DOI: 10.1111/cas.12862] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
352 Khodadoust MS, Alizadeh AA. Tumor antigen discovery through translation of the cancer genome. Immunol Res 2014;58:292-9. [PMID: 24718952 DOI: 10.1007/s12026-014-8505-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
353 Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845-1851. [PMID: 30397353 DOI: 10.1038/s41591-018-0232-2] [Cited by in Crossref: 282] [Cited by in F6Publishing: 280] [Article Influence: 70.5] [Reference Citation Analysis]
354 Mo J, Lin M, He B, Tan K, Jin C, Jiang H, Pan X, Lin W. Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Oncol Lett 2017;14:6829-32. [PMID: 29181104 DOI: 10.3892/ol.2017.7058] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
355 McCarthy CE, White JM, Viola NT, Gibson HM. In vivo Imaging Technologies to Monitor the Immune System. Front Immunol 2020;11:1067. [PMID: 32582173 DOI: 10.3389/fimmu.2020.01067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
356 Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol 2018;4:717-21. [PMID: 29423503 DOI: 10.1001/jamaoncol.2017.5332] [Cited by in Crossref: 114] [Cited by in F6Publishing: 113] [Article Influence: 38.0] [Reference Citation Analysis]
357 Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbé C, Svane IM, McNeil C, Rutkowski P, Loquai C, Mortier L, Hamid O, Bastholt L, Dreno B, Schadendorf D, Garbe C, Nyakas M, Grob JJ, Thomas L, Liszkay G, Smylie M, Hoeller C, Ferraresi V, Grange F, Gutzmer R, Pikiel J, Hosein F, Simsek B, Maio M. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J Immunother Cancer 2020;8:e000391. [PMID: 32503946 DOI: 10.1136/jitc-2019-000391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
358 Ikeda T, Yamaguchi H, Dotsu Y, Taniguchi H, Gyoutoku H, Senju H, Sakamoto N, Iwanaga S, Kuwatsuka Y, Fukuda M, Mukae H. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. Thorac Cancer. 2018;9:1522-1524. [PMID: 30253076 DOI: 10.1111/1759-7714.12872] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
359 Deniz B, Altincatal A, Ambavane A, Rao S, Doan J, Malcolm B, Michaelson MD, Yang S. Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS One 2018;13:e0203406. [PMID: 30161244 DOI: 10.1371/journal.pone.0203406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
360 Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010;16:311-7. [PMID: 20693841 DOI: 10.1097/PPO.0b013e3181eb3381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
361 Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017;14:549-61. [PMID: 28534531 DOI: 10.1038/nrclinonc.2017.71] [Cited by in Crossref: 151] [Cited by in F6Publishing: 160] [Article Influence: 30.2] [Reference Citation Analysis]
362 Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014;74:1993-2013. [PMID: 25344022 DOI: 10.1007/s40265-014-0305-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
363 Ji Y, Jin JY, Hyman DM, Kim G, Suri A. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology. Clin Transl Sci 2018;11:345-51. [PMID: 29392871 DOI: 10.1111/cts.12540] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
364 Toyota S, Orita H, Fukuyama Y, Motoyoshi S, Kawanami S, Maeda S, Kuramitsu E, Ichimanda M, Nagamatsu S, Nagata S, Kai S, Korenaga D, Mori M. Successful Conversion Surgery Following Chylous Ascites After Nivolumab for Advanced Gastric Cancer. In Vivo 2020;34:583-5. [PMID: 32111756 DOI: 10.21873/invivo.11810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
365 Dany M, Nganga R, Chidiac A, Hanna E, Matar S, Elston D. Advances in immunotherapy for melanoma management. Hum Vaccin Immunother 2016;12:2501-11. [PMID: 27454404 DOI: 10.1080/21645515.2016.1190889] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
366 Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology 2018;7:e1440168. [PMID: 29900043 DOI: 10.1080/2162402X.2018.1440168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
367 Martin-Romano P, Castanon E, Ammari S, Champiat S, Hollebecque A, Postel-Vinay S, Baldini C, Varga A, Michot JM, Vuagnat P, Marabelle A, Soria JC, Ferté C, Massard C. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Med 2020;9:2643-52. [PMID: 32074405 DOI: 10.1002/cam4.2797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
368 Eze C, Schmidt-Hegemann NS, Sawicki LM, Kirchner J, Roengvoraphoj O, Käsmann L, Mittlmeier LM, Kunz WG, Tufman A, Dinkel J, Ricke J, Belka C, Manapov F, Unterrainer M. PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging 2021. [PMID: 33760957 DOI: 10.1007/s00259-021-05211-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
369 Curry WT Jr, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res 2016;22:2885-96. [PMID: 26873960 DOI: 10.1158/1078-0432.CCR-15-2163] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
370 Mena E, Sanli Y, Marcus C, Subramaniam RM. Precision Medicine and PET/Computed Tomography in Melanoma. PET Clin 2017;12:449-58. [PMID: 28867115 DOI: 10.1016/j.cpet.2017.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
371 Studentova H, Kalabova H, Koranda P, Chytilova K, Kucerova L, Melichar B, Vrana D. Immunotherapy in mucosal melanoma: a case report and review of the literature. Oncotarget 2018;9:17971-7. [PMID: 29707161 DOI: 10.18632/oncotarget.24727] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
372 Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 2013;11:246. [PMID: 24093426 DOI: 10.1186/1479-5876-11-246] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
373 Ponomarev V. Advancing Immune and Cell-Based Therapies Through Imaging. Mol Imaging Biol 2017;19:379-84. [PMID: 28271366 DOI: 10.1007/s11307-017-1069-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
374 Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013;18:726-32. [PMID: 23716015 DOI: 10.1634/theoncologist.2012-0464] [Cited by in Crossref: 108] [Cited by in F6Publishing: 88] [Article Influence: 12.0] [Reference Citation Analysis]
375 D'Angelo SP, Tap WD, Schwartz GK, Carvajal RD. Sarcoma immunotherapy: past approaches and future directions. Sarcoma 2014;2014:391967. [PMID: 24778572 DOI: 10.1155/2014/391967] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
376 Verschraegen CF, Jerusalem G, McClay EF, Iannotti N, Redfern CH, Bennouna J, Chen FL, Kelly K, Mehnert J, Morris JC, Taylor M, Spigel D, Wang D, Grote HJ, Zhou D, Munshi N, Bajars M, Gulley JL. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer 2020;8:e001064. [PMID: 32907924 DOI: 10.1136/jitc-2020-001064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
377 Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clin Transl Sci. 2016;9:89-104. [PMID: 26924066 DOI: 10.1111/cts.12391] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 17.3] [Reference Citation Analysis]
378 Ouwerkerk W, van den Berg M, van der Niet S, Limpens J, Luiten RM. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Res 2019;29:453-64. [PMID: 30855527 DOI: 10.1097/CMR.0000000000000589] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
379 Taunk NK, Rimner A, Culligan M, Friedberg JS, Brahmer J, Chaft J. Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2017;6:178-85. [PMID: 28529900 DOI: 10.21037/tlcr.2017.03.05] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
380 Erinjeri JP, Fine GC, Adema GJ, Ahmed M, Chapiro J, den Brok M, Duran R, Hunt SJ, Johnson DT, Ricke J, Sze DY, Toskich BB, Wood BJ, Woodrum D, Goldberg SN. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper. Radiology 2019;292:25-34. [PMID: 31012818 DOI: 10.1148/radiol.2019182326] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
381 Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2014;2:17. [PMID: 24991412 DOI: 10.1186/2051-1426-2-17] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
382 Carter BW. Immunotherapy in Lung Cancer and the Role of Imaging. Semin Ultrasound CT MR 2018;39:314-21. [PMID: 29807642 DOI: 10.1053/j.sult.2018.02.004] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
383 Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014;6:63-75. [PMID: 24520205 DOI: 10.2147/CMAR.S57550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
384 Ritchie D, Colonna M. Mechanisms of Action and Clinical Development of Elotuzumab. Clin Transl Sci 2018;11:261-6. [PMID: 29272564 DOI: 10.1111/cts.12532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
385 Zhu Y, Liu J. The Role of Neoantigens in Cancer Immunotherapy. Front Oncol 2021;11:682325. [PMID: 34513673 DOI: 10.3389/fonc.2021.682325] [Reference Citation Analysis]
386 Li TL, Sun ZG, Jiang X, Guo HF. Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation. Oncol Lett 2017;13:4675-8. [PMID: 28599469 DOI: 10.3892/ol.2017.6087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
387 Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 2012;1:609-17. [PMID: 22934253 DOI: 10.4161/onci.20226] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 55.0] [Reference Citation Analysis]
388 Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 2013;19:2629-36. [PMID: 23669423 DOI: 10.1158/1078-0432.CCR-12-2935] [Cited by in Crossref: 60] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
389 Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD. Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol. 2011;344:211-244. [PMID: 20563707 DOI: 10.1007/82_2010_49] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
390 Xu Y, Wang M. [Progress in immunotherapy for non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:34-41. [PMID: 24398312 DOI: 10.3779/j.issn.1009-3419.2014.01.06] [Reference Citation Analysis]
391 Hartsough EJ, Basile KJ, Aplin AE. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res 2014;12:795-802. [PMID: 24520098 DOI: 10.1158/1541-7786.MCR-13-0581] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
392 Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Uchibori K, Yanagitani N, Horiike A, Horai T, Seike M, Gemma A, Nishio M. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. BMC Cancer. 2020;20:207. [PMID: 32164651 DOI: 10.1186/s12885-020-6704-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
393 Passler M, Taube ET, Sehouli J, Pietzner K. Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report. World J Clin Oncol 2019; 10(7): 247-255 [PMID: 31396474 DOI: 10.5306/wjco.v10.i7.247] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
394 Weis JA, Miga MI, Yankeelov TE. Three-dimensional Image-based Mechanical Modeling for Predicting the Response of Breast Cancer to Neoadjuvant Therapy. Comput Methods Appl Mech Eng 2017;314:494-512. [PMID: 28042181 DOI: 10.1016/j.cma.2016.08.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
395 Ross K, Jones RJ. Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci (Lond) 2017;131:2627-42. [PMID: 29079639 DOI: 10.1042/CS20160894] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 6.4] [Reference Citation Analysis]
396 Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, Tokita S, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nakae Y, Sugita O, Ito YM, Ota Y, Kimura Y, Kutomi G, Hirata K, Mizuguchi T, Imai K, Takemasa I, Sato N, Torigoe T. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Cancer Sci 2019;110:2378-85. [PMID: 31218770 DOI: 10.1111/cas.14106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
397 Carlin D, Weller A, Kramer G, Liu Y, Waterton JC, Chiti A, Sollini M, Joop de Langen A, O'Brien MER, Urbanowicz M, Jacobs BK, deSouza N. Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy. BJR Open 2019;1:20190029. [PMID: 33178953 DOI: 10.1259/bjro.20190029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
398 Malissen N, Grob JJ. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. Drugs 2018;78:1197-209. [PMID: 30097888 DOI: 10.1007/s40265-018-0945-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
399 Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M, Yamazaki N. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016;7:77404-15. [PMID: 27764805 DOI: 10.18632/oncotarget.12677] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 25.0] [Reference Citation Analysis]
400 Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37. [PMID: 24247168 DOI: 10.1038/nrclinonc.2013.208] [Cited by in Crossref: 271] [Cited by in F6Publishing: 249] [Article Influence: 30.1] [Reference Citation Analysis]
401 Guo H, Li W, Qian L, Cui J. Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. Chin J Cancer Res 2021;33:203-15. [PMID: 34158740 DOI: 10.21147/j.issn.1000-9604.2021.02.08] [Reference Citation Analysis]
402 Kuhara Y, Ninomiya M, Hirahara S, Doi H, Kenji S, Toyota K, Yano R, Kobayashi H, Hashimoto Y, Yokoyama Y, Sakashita Y, Miyamoto K. A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect. Int Cancer Conf J 2020;9:193-8. [PMID: 32904110 DOI: 10.1007/s13691-020-00433-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
403 Moskovitz JM, Ferris RL. Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. J Dent Res 2018;97:622-6. [PMID: 29489423 DOI: 10.1177/0022034518759464] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
404 Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015;33:1889-94. [PMID: 25667295 DOI: 10.1200/JCO.2014.56.2736] [Cited by in Crossref: 1222] [Cited by in F6Publishing: 667] [Article Influence: 174.6] [Reference Citation Analysis]
405 Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol 2015;84:1259-68. [PMID: 25937524 DOI: 10.1016/j.ejrad.2015.03.017] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
406 Pozzessere C, Bassanelli M, Ceribelli A, Rasul S, Li S, Prior JO, Cicone F. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer? Curr Urol Rep 2019;20:68. [PMID: 31605269 DOI: 10.1007/s11934-019-0938-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
407 Wilson RAM, Evans TRJ, Fraser AR, Nibbs RJB. Immune checkpoint inhibitors: new strategies to checkmate cancer. Clin Exp Immunol. 2018;191:133-148. [PMID: 29139554 DOI: 10.1111/cei.13081] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
408 Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, Parisi E, Romeo A, Guidoboni M. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med 2014;12:262. [PMID: 25245327 DOI: 10.1186/s12967-014-0262-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
409 Dercle L, Ammari S, Bateson M, Durand PB, Haspinger E, Massard C, Jaudet C, Varga A, Deutsch E, Soria JC, Ferté C. Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep 2017;7:7952. [PMID: 28801575 DOI: 10.1038/s41598-017-08310-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
410 Shimanovsky A, Dasanu CA. Updates on immunotherapy in non-small cell lung cancer. Expert Opin Biol Ther 2014;14:411-8. [PMID: 24512518 DOI: 10.1517/14712598.2014.887675] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
411 Rossi SH, Prezzi D, Kelly-Morland C, Goh V. Imaging for the diagnosis and response assessment of renal tumours. World J Urol 2018;36:1927-42. [PMID: 29948048 DOI: 10.1007/s00345-018-2342-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
412 Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Ann Surg Oncol 2020;27:1180-8. [PMID: 31848819 DOI: 10.1245/s10434-019-08099-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
413 Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol 2016;34:3787-95. [PMID: 27269940 DOI: 10.1200/JCO.2015.65.5142] [Cited by in Crossref: 57] [Cited by in F6Publishing: 35] [Article Influence: 11.4] [Reference Citation Analysis]
414 O'Sullivan Coyne G, Gulley JL. Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014;10:3306-12. [PMID: 25483630 DOI: 10.4161/21645515.2014.973318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
415 Alsina M, Moehler M, Hierro C, Guardeño R, Tabernero J. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Target Oncol 2016;11:469-77. [PMID: 26880697 DOI: 10.1007/s11523-016-0421-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
416 Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2018;13:831-9. [PMID: 29578107 DOI: 10.1016/j.jtho.2018.03.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
417 Liberini V, Mariniello A, Righi L, Capozza M, Delcuratolo MD, Terreno E, Farsad M, Volante M, Novello S, Deandreis D. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers (Basel) 2021;13:4543. [PMID: 34572771 DOI: 10.3390/cancers13184543] [Reference Citation Analysis]
418 Oft M. Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience. Semin Immunol 2019;44:101325. [PMID: 31706853 DOI: 10.1016/j.smim.2019.101325] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
419 Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov 2019;9:370-83. [PMID: 30409776 DOI: 10.1158/2159-8290.CD-18-0774] [Cited by in Crossref: 152] [Cited by in F6Publishing: 104] [Article Influence: 38.0] [Reference Citation Analysis]
420 Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer 2015;1:66-75. [PMID: 26457331 DOI: 10.1016/j.trecan.2015.07.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
421 Kim JY, Lee KH, Kang J, Borcoman E, Saada-Bouzid E, Kronbichler A, Hong SH, de Rezende LFM, Ogino S, Keum N, Song M, Luchini C, van der Vliet HJ, Shin JI, Gamerith G. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31683809 DOI: 10.3390/cancers11111699] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
422 Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. Front Immunol 2021;12:663865. [PMID: 34046035 DOI: 10.3389/fimmu.2021.663865] [Reference Citation Analysis]
423 Seith F, Forschner A, Schmidt H, Pfannenberg C, Gückel B, Nikolaou K, la Fougère C, Garbe C, Schwenzer N. 18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. Eur J Nucl Med Mol Imaging 2018;45:95-101. [PMID: 28831583 DOI: 10.1007/s00259-017-3813-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
424 Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 2016;27:1291-8. [PMID: 27117531 DOI: 10.1093/annonc/mdw174] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 12.8] [Reference Citation Analysis]
425 . Current world literature. Curr Opin Oncol 2011;23:227-34. [PMID: 21307677 DOI: 10.1097/CCO.0b013e328344b687] [Reference Citation Analysis]
426 Han Z, Ke M, Liu X, Wang J, Guan Z, Qiao L, Wu Z, Sun Y, Sun X. Molecular Imaging, How Close to Clinical Precision Medicine in Lung, Brain, Prostate and Breast Cancers. Mol Imaging Biol 2021. [PMID: 34269972 DOI: 10.1007/s11307-021-01631-y] [Reference Citation Analysis]
427 Gerritsen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2012;32:25-35. [PMID: 22048979 DOI: 10.1007/s10875-011-9595-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
428 Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:16. [PMID: 28239469 DOI: 10.1186/s40425-017-0218-5] [Cited by in Crossref: 191] [Cited by in F6Publishing: 176] [Article Influence: 38.2] [Reference Citation Analysis]
429 Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci 2020;21:E8984. [PMID: 33256089 DOI: 10.3390/ijms21238984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
430 Wang R, Zhang Y, Shan F. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer? Int Immunopharmacol 2021;103:108484. [PMID: 34954558 DOI: 10.1016/j.intimp.2021.108484] [Reference Citation Analysis]
431 Tuyaerts S. Dendritic cell therapy for oncology roundtable conference. J Immune Based Ther Vaccines 2011;9:1. [PMID: 21226916 DOI: 10.1186/1476-8518-9-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
432 Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97. [PMID: 20826737 DOI: 10.1093/jnci/djq310] [Cited by in Crossref: 393] [Cited by in F6Publishing: 326] [Article Influence: 32.8] [Reference Citation Analysis]
433 Cuzzubbo S, Tetu P, Guegan S, Ursu R, Belin C, Sirven Villaros L, Mazoyer J, Lheure C, Lebbe C, Baroudjian B, Carpentier AF. Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. J Immunother Cancer 2020;8:e001034. [PMID: 32747471 DOI: 10.1136/jitc-2020-001034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
434 Seith F, Forschner A, Weide B, Gückel B, Schwartz M, Schwenck J, Othman AE, Fenchel M, Garbe C, Nikolaou K, Schwenzer N, la Fougère C, Pfannenberg C. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer 2020;8:e000656. [PMID: 32753543 DOI: 10.1136/jitc-2020-000656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
435 Qiu Y, Tan M, McMeekin S, Thai T, Ding K, Moore K, Liu H, Zheng B. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol 2016;57:1149-55. [PMID: 26663390 DOI: 10.1177/0284185115620947] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
436 Zhang L, Han X, Shi Y. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. JAMA Netw Open 2020;3:e2013201. [PMID: 32845327 DOI: 10.1001/jamanetworkopen.2020.13201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
437 Sachpekidis C, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study. EJNMMI Res 2021;11:89. [PMID: 34495433 DOI: 10.1186/s13550-021-00832-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Le DT, Jaffee EM. Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw. 2013;11:766-772. [PMID: 23847215 DOI: 10.6004/jnccn.2013.0099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
439 Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira SI, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K. Guidelines for clinical evaluation of anti-cancer drugs. Cancer Sci 2021;112:2563-77. [PMID: 33990993 DOI: 10.1111/cas.14967] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
440 Lin Z, Liu Q, Wei Q, Lin L, Chen X, Xue D. Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports. Ann Transl Med 2020;8:1100. [PMID: 33145319 DOI: 10.21037/atm-20-3928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Hufnagel S, Xu H, Colemam MF, Valdes SA, Liu KA, Hursting SD, Cui Z. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent. Cancer Chemother Pharmacol 2021. [PMID: 34698902 DOI: 10.1007/s00280-021-04367-2] [Reference Citation Analysis]
442 Scott JA, Wang Y. FDG PET Is a Better Canary in the Coal Mine than CT for Refractory Lymphoma. Radiology 2020;295:662-3. [PMID: 32293222 DOI: 10.1148/radiol.2020200575] [Reference Citation Analysis]
443 Kaufman HL, Andtbacka RHI, Collichio FA, Wolf M, Zhao Z, Shilkrut M, Puzanov I, Ross M. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J Immunother Cancer 2017;5:72. [PMID: 28923101 DOI: 10.1186/s40425-017-0276-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
444 Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, Shariat SF. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol. 2018;36:1703-1709. [PMID: 29549485 DOI: 10.1007/s00345-018-2264-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
445 Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo. Sci Immunol 2017;2:eaal2568. [PMID: 28367538 DOI: 10.1126/sciimmunol.aal2568] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
446 Shepherd FA, Douillard JY, Blumenschein GR. [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. Zhongguo Fei Ai Za Zhi 2013;16:C9-20. [PMID: 23601304 DOI: 10.3779/j.issn.1009-3419.2013.04.09] [Reference Citation Analysis]
447 Kudrin A. Overview of cancer vaccines: considerations for development. Hum Vaccin Immunother. 2012;8:1335-1353. [PMID: 22894970 DOI: 10.4161/hv.20518] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
448 Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207-211. [PMID: 26359337 DOI: 10.1126/science.aad0095] [Cited by in Crossref: 1413] [Cited by in F6Publishing: 1291] [Article Influence: 201.9] [Reference Citation Analysis]
449 Park H, Sholl LM, Hatabu H, Awad MM, Nishino M. Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology 2019;293:15-29. [PMID: 31385753 DOI: 10.1148/radiol.2019190173] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
450 Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016;34:1510-1517. [PMID: 26951310 DOI: 10.1200/jco.2015.64.0391] [Cited by in Crossref: 466] [Cited by in F6Publishing: 229] [Article Influence: 77.7] [Reference Citation Analysis]
451 Yarchoan M, Huang CY, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL 2nd, Nauroth JM, Rodriguez C, Osipov A, De Jesus-Acosta A, Le DT, Murphy AG, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med 2020;9:1485-94. [PMID: 31876399 DOI: 10.1002/cam4.2763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
452 Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Mol Cancer Ther 2015;14:1680-92. [PMID: 25948295 DOI: 10.1158/1535-7163.MCT-15-0080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
453 Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res 2018;24:4416-28. [PMID: 29848573 DOI: 10.1158/1078-0432.CCR-17-3649] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
454 Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. J Transl Med 2017;15:150. [PMID: 28662677 DOI: 10.1186/s12967-017-1251-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
455 Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1-13. [PMID: 23772560 DOI: 10.1111/nyas.12180] [Cited by in Crossref: 192] [Cited by in F6Publishing: 172] [Article Influence: 21.3] [Reference Citation Analysis]
456 Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015;125:3377-83. [PMID: 26325034 DOI: 10.1172/JCI80012] [Cited by in Crossref: 87] [Cited by in F6Publishing: 55] [Article Influence: 12.4] [Reference Citation Analysis]
457 Shah S, Ward JE, Bao R, Hall CR, Brockstein BE, Luke JJ. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. Cancer Immunol Res 2016;4:903-9. [PMID: 27638840 DOI: 10.1158/2326-6066.CIR-16-0087] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
458 Wang ZX, Wu HX, Xie L, Wang YN, Yang LP, He MM, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open 2019;2:e193433. [PMID: 31050784 DOI: 10.1001/jamanetworkopen.2019.3433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
459 Neagu MR, Reardon DA. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Curr Treat Options Oncol 2015;16:54. [PMID: 26454859 DOI: 10.1007/s11864-015-0371-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
460 Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, Richtig M, Grübler MR, Gappmayer A, Haidn T, Kofler J, Huegel R, Lange-Asschenfeldt B, Pichler M, Pilz S, Heinemann A, Richtig E. Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PLoS One 2018;13:e0204729. [PMID: 30273398 DOI: 10.1371/journal.pone.0204729] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
461 Iafrate M, Fruhwirth GO. How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. Front Physiol 2020;11:154. [PMID: 32327996 DOI: 10.3389/fphys.2020.00154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
462 Li X, Ferrel GL, Guerra MC, Hode T, Lunn JA, Adalsteinsson O, Nordquist RE, Liu H, Chen WR. Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochem Photobiol Sci 2011;10:817-21. [PMID: 21373701 DOI: 10.1039/c0pp00306a] [Cited by in Crossref: 74] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
463 Virostko J, Hainline A, Kang H, Arlinghaus LR, Abramson RG, Barnes SL, Blume JD, Avery S, Patt D, Goodgame B, Yankeelov TE, Sorace AG. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis. J Med Imaging (Bellingham) 2018;5:011011. [PMID: 29201942 DOI: 10.1117/1.JMI.5.1.011011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
464 Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228-241. [PMID: 26667975 DOI: 10.1038/nrclinonc.2015.215] [Cited by in Crossref: 331] [Cited by in F6Publishing: 324] [Article Influence: 47.3] [Reference Citation Analysis]
465 Harrington KJ, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger AL, Dummer R. A practical guide to the handling and administration of talimogene laherparepvec in Europe.Onco Targets Ther. 2017;10:3867-3880. [PMID: 28814886 DOI: 10.2147/OTT.S133699] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
466 Watanabe Y, Ogawa M, Tamura Y, Suda S, Kaneko M, Kumagawa M, Hirayama M, Matsumoto N, Yamamoto T, Moriyama M. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. J Investig Med High Impact Case Rep 2021;9:23247096211058489. [PMID: 34845921 DOI: 10.1177/23247096211058489] [Reference Citation Analysis]
467 Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 2015;8:929-37. [PMID: 25960664 DOI: 10.2147/OTT.S53164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
468 Kreamer KM. Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. J Adv Pract Oncol 2014;5:418-31. [PMID: 26328216 DOI: 10.6004/jadpro.2014.5.6.3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 22] [Article Influence: 0.3] [Reference Citation Analysis]
469 Raimondi A, Randon G, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. Int J Mol Sci 2019;20:E4263. [PMID: 31480348 DOI: 10.3390/ijms20174263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
470 Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;12:55. [PMID: 24565030 DOI: 10.1186/1479-5876-12-55] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
471 Simard JL, Smith M, Chandra S. Pseudoprogression of Melanoma Brain Metastases. Curr Oncol Rep 2018;20:91. [PMID: 30413981 DOI: 10.1007/s11912-018-0722-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
472 Devkota L, Starosolski Z, Rivas CH, Stupin I, Annapragada A, Ghaghada KB, Parihar R. Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics. Sci Adv 2020;6:eaba6156. [PMID: 32832602 DOI: 10.1126/sciadv.aba6156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
473 Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2013;79:283-8. [PMID: 23254265 DOI: 10.1016/j.lungcan.2012.11.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
474 Morgan B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol 2011;8:517-27. [PMID: 21522122 DOI: 10.1038/nrclinonc.2011.62] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
475 George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol 2016;2:1179-86. [PMID: 27243803 DOI: 10.1001/jamaoncol.2016.0775] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
476 Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res 2018;24:1872-80. [PMID: 29330207 DOI: 10.1158/1078-0432.CCR-17-1341] [Cited by in Crossref: 123] [Cited by in F6Publishing: 90] [Article Influence: 30.8] [Reference Citation Analysis]
477 Hao Z, Biddinger P, Schroeder C, Tariq K. Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. BMJ Case Rep 2016;2016:bcr2016215304. [PMID: 27389724 DOI: 10.1136/bcr-2016-215304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
478 Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014;5:1392-433. [PMID: 24722523 DOI: 10.18632/oncotarget.1891] [Cited by in Crossref: 111] [Cited by in F6Publishing: 110] [Article Influence: 15.9] [Reference Citation Analysis]
479 Dudek AZ, Liu LC, Gupta S, Logan TF, Singer EA, Joshi M, Zakharia YN, Lang JM, Schwarz JK, Al-Janadi A, Alva AS. Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. J Clin Oncol. 2020;38:1138-1145. [PMID: 32097091 DOI: 10.1200/jco.19.02394] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
480 Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer 2021;9:e001752. [PMID: 33849924 DOI: 10.1136/jitc-2020-001752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
481 Provencio M, Torrente M, Calvo V, Gutiérrez L, Pérez-Callejo D, Pérez-Barrios C, Barquín M, Royuela A, Rodriguez-Alfonso B, Sotelo M, Cruz-Bermúdez JL, Mendez M, Cruz-Bermúdez A, Romero A. Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment. Oncotarget 2017;8:60291-8. [PMID: 28947971 DOI: 10.18632/oncotarget.20016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
482 Haque S, Yellu M, Randhawa J, Hashemi-Sadraei N. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Des Devel Ther 2017;11:2537-49. [PMID: 28919706 DOI: 10.2147/DDDT.S119537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
483 Philips R, Han C, Swendseid B, Curry J, Argiris A, Luginbuhl A, Johnson J. Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. Front Oncol 2021;11:682075. [PMID: 34277428 DOI: 10.3389/fonc.2021.682075] [Reference Citation Analysis]
484 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
485 Giavina-Bianchi MH, Giavina-Bianchi PF Junior, Festa C Neto. Melanoma: tumor microenvironment and new treatments. An Bras Dermatol 2017;92:156-66. [PMID: 28538872 DOI: 10.1590/abd1806-4841.20176183] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
486 Koido S, Homma S, Takahara A, Namiki Y, Komita H, Nagasaki E, Ito M, Nagatsuma K, Uchiyama K, Satoh K, Ohkusa T, Gong J, Tajiri H. Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J Biomed Biotechnol 2011;2011:910836. [PMID: 21541197 DOI: 10.1155/2011/910836] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
487 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54. [PMID: 22658127 DOI: 10.1056/NEJMoa1200690] [Cited by in Crossref: 7634] [Cited by in F6Publishing: 4584] [Article Influence: 763.4] [Reference Citation Analysis]
488 Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J. Immune Checkpoint in Glioblastoma: Promising and Challenging. Front Pharmacol 2017;8:242. [PMID: 28536525 DOI: 10.3389/fphar.2017.00242] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 14.4] [Reference Citation Analysis]
489 Levine O, Devji T, Xie F. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Hum Vaccin Immunother 2017;13:1765-7. [PMID: 28481695 DOI: 10.1080/21645515.2017.1322241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
490 Schlemmer HP, Bittencourt LK, D'Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H. Global Challenges for Cancer Imaging. J Glob Oncol 2018;4:1-10. [PMID: 30241164 DOI: 10.1200/JGO.17.00036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
491 Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015;92:368-75. [PMID: 25754629 DOI: 10.1016/j.ijrobp.2015.01.004] [Cited by in Crossref: 230] [Cited by in F6Publishing: 222] [Article Influence: 32.9] [Reference Citation Analysis]
492 Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med. 2013;11:97. [PMID: 23578144 DOI: 10.1186/1479-5876-11-97] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
493 Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350-1355. [PMID: 29567705 DOI: 10.1126/science.aar4060] [Cited by in Crossref: 1860] [Cited by in F6Publishing: 1791] [Article Influence: 465.0] [Reference Citation Analysis]
494 Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 2017;8:607. [PMID: 28928360 DOI: 10.1038/s41467-017-00452-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 13.6] [Reference Citation Analysis]
495 Shklovskaya E, Lee JH, Lim SY, Stewart A, Pedersen B, Ferguson P, Saw RP, Thompson JF, Shivalingam B, Carlino MS, Scolyer RA, Menzies AM, Long GV, Kefford RF, Rizos H. Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers (Basel) 2020;12:E3374. [PMID: 33202676 DOI: 10.3390/cancers12113374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
496 Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol. 2017;10:168-194. [PMID: 28286568 DOI: 10.1177/1756283x16667909] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
497 Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, Wong P, Singer S, Ariyan C, Bartlett EK, Crago A, Yoon S, Hwang S, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA Oncol 2020;6:402-8. [PMID: 31971541 DOI: 10.1001/jamaoncol.2019.6152] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 17.0] [Reference Citation Analysis]
498 Tang X, Liu T, Zang X, Liu H, Wang D, Chen H, Zhang B. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS One 2013;8:e62847. [PMID: 23667530 DOI: 10.1371/journal.pone.0062847] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
499 Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology 2016;5:e1143997. [PMID: 27467964 DOI: 10.1080/2162402X.2016.1143997] [Cited by in Crossref: 50] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
500 Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT Jr, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro Oncol 2014;16:1441-58. [PMID: 25190673 DOI: 10.1093/neuonc/nou212] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 14.0] [Reference Citation Analysis]
501 Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS, Awad MM. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 2016;4:84. [PMID: 28018599 DOI: 10.1186/s40425-016-0193-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
502 Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol 2019;5:393-401. [PMID: 30676622 DOI: 10.1001/jamaoncol.2018.6258] [Cited by in Crossref: 138] [Cited by in F6Publishing: 131] [Article Influence: 46.0] [Reference Citation Analysis]
503 Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015;4:e1046028. [PMID: 26451318 DOI: 10.1080/2162402X.2015.1046028] [Cited by in Crossref: 154] [Cited by in F6Publishing: 79] [Article Influence: 22.0] [Reference Citation Analysis]
504 Burns MC, O'Donnell A, Puzanov I. Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016;4:867-73. [PMID: 27597930 DOI: 10.1080/21678707.2016.1191348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
505 Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer 2018;6:93. [PMID: 30253804 DOI: 10.1186/s40425-018-0407-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
506 Chia PL, Gedye C, Boutros PC, Wheatley-Price P, John T. Current and Evolving Methods to Visualize Biological Data in Cancer Research. J Natl Cancer Inst 2016;108:djw031. [PMID: 27245079 DOI: 10.1093/jnci/djw031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
507 Nguyen NC, Yee MK, Tuchayi AM, Kirkwood JM, Tawbi H, Mountz JM. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Front Oncol 2018;8:18. [PMID: 29520339 DOI: 10.3389/fonc.2018.00018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
508 DeMaria PJ, Bilusic M, Park DM, Heery CR, Donahue RN, Madan RA, Bagheri MH, Strauss J, Shen V, Marté JL, Steinberg SM, Schlom J, Gilbert MR, Gulley JL. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. Oncologist 2021;26:e847-58. [PMID: 33594772 DOI: 10.1002/onco.13720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
509 Lynes JP, Nwankwo AK, Sur HP, Sanchez VE, Sarpong KA, Ariyo OI, Dominah GA, Nduom EK. Biomarkers for immunotherapy for treatment of glioblastoma. J Immunother Cancer 2020;8:e000348. [PMID: 32474411 DOI: 10.1136/jitc-2019-000348] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
510 Moaven O, W Mangieri C, A Stauffer J, Anastasiadis PZ, Borad MJ. Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. JCO Precis Oncol 2021;5:PO. [PMID: 34250386 DOI: 10.1200/PO.20.00395] [Reference Citation Analysis]
511 Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer 2015;51:2689-97. [PMID: 26364516 DOI: 10.1016/j.ejca.2015.08.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
512 Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen JHT, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma 2021;:1-13. [PMID: 34865586 DOI: 10.1080/10428194.2021.2010057] [Reference Citation Analysis]
513 Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: First in class oncolytic virotherapy. Hum Vaccin Immunother 2018;14:839-46. [PMID: 29420123 DOI: 10.1080/21645515.2017.1412896] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 32.3] [Reference Citation Analysis]
514 Aquino D, Gioppo A, Finocchiaro G, Bruzzone MG, Cuccarini V. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. J Immunol Res 2017;2017:5813951. [PMID: 28512646 DOI: 10.1155/2017/5813951] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
515 Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ. Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep 2017;7:807. [PMID: 28400597 DOI: 10.1038/s41598-017-01000-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
516 Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol 2018;15:112-24. [PMID: 29205200 DOI: 10.1038/nrurol.2017.190] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
517 Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics 2019;9:5085-104. [PMID: 31410203 DOI: 10.7150/thno.34415] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
518 Zhao Q, Bi Y, Sun H, Xiao M. Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients. Dis Markers 2021;2021:5526885. [PMID: 34239620 DOI: 10.1155/2021/5526885] [Reference Citation Analysis]
519 Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol 2015;33:3541-3. [PMID: 26261262 DOI: 10.1200/JCO.2015.61.6870] [Cited by in Crossref: 469] [Cited by in F6Publishing: 263] [Article Influence: 67.0] [Reference Citation Analysis]
520 Kelly-Morland C, Rudman S, Nathan P, Mallett S, Montana G, Cook G, Goh V. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. BMC Cancer 2017;17:392. [PMID: 28578690 DOI: 10.1186/s12885-017-3371-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
521 Amin S, Bathe OF. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer 2016;16:850. [PMID: 27814715 DOI: 10.1186/s12885-016-2886-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
522 Herbreteau G, Vallée A, Knol AC, Théoleyre S, Quéreux G, Varey E, Khammari A, Dréno B, Denis MG. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget 2018;9:25265-76. [PMID: 29861869 DOI: 10.18632/oncotarget.25404] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
523 Frelaut M, Le Tourneau C, Borcoman E. Hyperprogression under Immunotherapy. Int J Mol Sci 2019;20:E2674. [PMID: 31151303 DOI: 10.3390/ijms20112674] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
524 Ren Z, Qin S, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Yan P, Zou J. A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer 2021;10:500-9. [PMID: 34721511 DOI: 10.1159/000516470] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. Br J Clin Pharmacol 2020;86:1736-52. [PMID: 32384184 DOI: 10.1111/bcp.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
526 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 44] [Article Influence: 13.6] [Reference Citation Analysis]
527 De Mattos-Arruda L, Blanco-Heredia J, Aguilar-Gurrieri C, Carrillo J, Blanco J. New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open 2020;4:e000684. [PMID: 32269031 DOI: 10.1136/esmoopen-2020-000684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
528 Trinh VA, Hagen B. Ipilimumab for advanced melanoma: a pharmacologic perspective. J Oncol Pharm Pract 2013;19:195-201. [PMID: 23047236 DOI: 10.1177/1078155212459100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
529 Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013;2:e26218. [PMID: 24179709 DOI: 10.4161/onci.26218] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
530 Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, Ulery T, Kukreja A, Li L, Bedrosian CL, Zhang X, Heffner LT. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer 2019;7:227. [PMID: 31443741 DOI: 10.1186/s40425-019-0710-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
531 Yu D, Yang J, Jin M, Zhou B, Shi L, Zhao L, Zhang J, Lin Z, Ren J, Liu L, Zhang T, Liu H. Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis. mBio 2021;12:e0299421. [PMID: 34872346 DOI: 10.1128/mBio.02994-21] [Reference Citation Analysis]
532 Marsavela G, McEvoy AC, Pereira MR, Reid AL, Al-Ogaili Z, Warburton L, Khattak MA, Abed A, Meniawy TM, Millward M, Ziman MR, Calapre L, Gray ES. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. Br J Cancer 2021. [PMID: 34373567 DOI: 10.1038/s41416-021-01507-6] [Reference Citation Analysis]
533 Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther 2012;20:679-86. [PMID: 22186789 DOI: 10.1038/mt.2011.269] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 9.9] [Reference Citation Analysis]
534 Wiseman M D C. Questions from the fourth son: a clinician reflects on immunomonitoring, surrogate markers and systems biology. Math Biosci Eng 2011;8:279-87. [PMID: 21631130 DOI: 10.3934/mbe.2011.8.279] [Reference Citation Analysis]
535 Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18:1874-84. [PMID: 20664527 DOI: 10.1038/mt.2010.161] [Cited by in Crossref: 155] [Cited by in F6Publishing: 158] [Article Influence: 12.9] [Reference Citation Analysis]
536 Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res 2019;25:5493-502. [PMID: 31126960 DOI: 10.1158/1078-0432.CCR-18-2992] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 17.7] [Reference Citation Analysis]
537 Dörrie J, Schaft N, Schuler G, Schuler-Thurner B. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. Pharmaceutics 2020;12:E92. [PMID: 31979205 DOI: 10.3390/pharmaceutics12020092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
538 Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 2018;45:1289-96. [PMID: 29478079 DOI: 10.1007/s00259-018-3972-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
539 Subbiah V, Chuang HH, Gambhire D, Kairemo K. Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics (Basel) 2017;7:E10. [PMID: 28212290 DOI: 10.3390/diagnostics7010010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
540 McCracken MN, Tavaré R, Witte ON, Wu AM. Advances in PET Detection of the Antitumor T Cell Response. Adv Immunol 2016;131:187-231. [PMID: 27235684 DOI: 10.1016/bs.ai.2016.02.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
541 Anbil S, Rizvi I, Celli JP, Alagic N, Pogue BW, Hasan T. Impact of treatment response metrics on photodynamic therapy planning and outcomes in a three-dimensional model of ovarian cancer. J Biomed Opt 2013;18:098004. [PMID: 24802230 DOI: 10.1117/1.JBO.18.9.098004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
542 Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer 2019;7:354. [PMID: 31856918 DOI: 10.1186/s40425-019-0813-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 23.3] [Reference Citation Analysis]
543 Chiarion Sileni V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di Guardo L, Marchetti P, de Rosa F, Nuzzo C, Testori A, Cocorocchio E, Bernengo MG, Guida M, Marconcini R, Merelli B, Parmiani G, Rinaldi G, Aglietta M, Grosso M, Queirolo P. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 2014;33:30. [PMID: 24708900 DOI: 10.1186/1756-9966-33-30] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 8.8] [Reference Citation Analysis]
544 Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol 2018;4:1583-8. [PMID: 29931076 DOI: 10.1001/jamaoncol.2018.1888] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
545 Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Res 2017;27:358-68. [PMID: 28509765 DOI: 10.1097/CMR.0000000000000359] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
546 LaSalle T, Austin EE, Rigney G, Wehrenberg-Klee E, Nesti S, Larimer B, Mahmood U. Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response. J Immunother Cancer 2020;8:e000291. [PMID: 32461343 DOI: 10.1136/jitc-2019-000291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
547 Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567. [PMID: 25428504 DOI: 10.1038/nature14011] [Cited by in Crossref: 2878] [Cited by in F6Publishing: 2815] [Article Influence: 411.1] [Reference Citation Analysis]
548 Johnson P, Greiner W, Al-Dakkak I, Wagner S. Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? Biomed Res Int 2015;2015:865101. [PMID: 26161418 DOI: 10.1155/2015/865101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
549 Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L, Lutzky J, Luna TL, Aung S, Lawson DH. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. J Immunother Cancer 2018;6:76. [PMID: 30053905 DOI: 10.1186/s40425-018-0387-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
550 Cao XX, Niu N, Sun J, Cai H, Wang FD, Wang YN, Duan MH, Zhou DB, Li J. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis 2019;14:11. [PMID: 30630516 DOI: 10.1186/s13023-018-0988-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
551 Hamid O, Ismail R, Puzanov I. Intratumoral Immunotherapy-Update 2019. Oncologist 2020;25:e423-38. [PMID: 32162802 DOI: 10.1634/theoncologist.2019-0438] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
552 Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9:8. [PMID: 30694399 DOI: 10.1186/s13550-019-0473-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
553 Guldbrandsen KF, Hendel HW, Langer SW, Fischer BM. Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics (Basel) 2017;7:E23. [PMID: 28430133 DOI: 10.3390/diagnostics7020023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
554 Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 2015;33:621-31. [PMID: 25822109 DOI: 10.1007/s10637-015-0226-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
555 Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol 2013;200:475-83. [PMID: 23436834 DOI: 10.2214/AJR.12.9049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
556 Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 2020;8:e000537. [PMID: 33106386 DOI: 10.1136/jitc-2020-000537] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
557 Aide N, Fanti S. Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. Eur J Nucl Med Mol Imaging 2017;44:1-3. [PMID: 28540418 DOI: 10.1007/s00259-017-3721-5] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
558 Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558-562. [PMID: 25428503 DOI: 10.1038/nature13904] [Cited by in Crossref: 1564] [Cited by in F6Publishing: 1486] [Article Influence: 223.4] [Reference Citation Analysis]
559 Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol 2012;23 Suppl 8:viii15-21. [PMID: 22918923 DOI: 10.1093/annonc/mds258] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
560 Long GV. From dismal prognosis to rising star: melanoma leading the way with new generation cancer therapies. Med J Aust 2015;202:115-6. [PMID: 25669459 DOI: 10.5694/mja14.01718] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
561 Sluka P, Davis ID. Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol 2013;10:441-51. [PMID: 23857181 DOI: 10.1038/nrurol.2013.146] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
562 Kok PS, Yoon WH, Lord S, Marschner I, Friedlander M, Lee CK. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. JCO Precis Oncol 2021;5:PO. [PMID: 34296055 DOI: 10.1200/PO.21.00108] [Reference Citation Analysis]
563 Yang D. Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. Neurooncol Pract 2016;3:59-67. [PMID: 31579522 DOI: 10.1093/nop/npv023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
564 Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ. Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma. Am J Clin Oncol 2014;37:261-5. [PMID: 23241505 DOI: 10.1097/COC.0b013e318277d5c8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
565 Tovoli F, Renzulli M, Granito A, Golfieri R, Bolondi L. Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. Hepat Oncol 2017;4:129-37. [PMID: 30191059 DOI: 10.2217/hep-2017-0018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
566 Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-52. [PMID: 28271869 DOI: 10.1016/S1470-2045(17)30074-8] [Cited by in Crossref: 807] [Cited by in F6Publishing: 445] [Article Influence: 161.4] [Reference Citation Analysis]
567 Liu J, Zhang S, Li H, Cheng Y. [Advances of immunotherapy in small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:474-80. [PMID: 24949688 DOI: 10.3779/j.issn.1009-3419.2014.06.07] [Reference Citation Analysis]
568 Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Front Oncol 2019;9:1483. [PMID: 31998643 DOI: 10.3389/fonc.2019.01483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
569 Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014;6:232ra51. [PMID: 24739759 DOI: 10.1126/scitranslmed.3008068] [Cited by in Crossref: 198] [Cited by in F6Publishing: 198] [Article Influence: 24.8] [Reference Citation Analysis]
570 Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol 2016;11:1511-21. [PMID: 27296105 DOI: 10.1016/j.jtho.2016.05.028] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
571 Suzuki H, Owada Y, Watanabe Y, Inoue T, Fukuharav M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Ohsugi J, Hoshino M, Higuchi M, Shio Y, Gotoh M. Recent advances in immunotherapy for non-small-cell lung cancer. Hum Vaccin Immunother 2014;10:352-7. [PMID: 24196313 DOI: 10.4161/hv.26919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
572 Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011;9:214. [PMID: 22168571 DOI: 10.1186/1479-5876-9-214] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 10.7] [Reference Citation Analysis]
573 Anderson KL, Modiano JF. Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure. Vet Sci 2015;2:363-87. [PMID: 27066495 DOI: 10.3390/vetsci2040363] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
574 Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010;16:6029-39. [PMID: 21169255 DOI: 10.1158/1078-0432.CCR-10-1490] [Cited by in Crossref: 63] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
575 Merhi M, Raza A, Inchakalody VP, Nashwan AJJ, Allahverdi N, Krishnankutty R, Uddin S, Zar Gul AR, Al Homsi MU, Dermime S. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. Front Immunol 2018;9:1769. [PMID: 30108590 DOI: 10.3389/fimmu.2018.01769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
576 Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U, Glas M. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Neuro Oncol 2016;18:1462-4. [PMID: 27591333 DOI: 10.1093/neuonc/now154] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
577 Mclean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, Fox C, Kleid S, Rischin D. Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. Front Oncol 2022;11:796197. [DOI: 10.3389/fonc.2021.796197] [Reference Citation Analysis]
578 Lopci E. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. J Clin Med 2021;10:5160. [PMID: 34768681 DOI: 10.3390/jcm10215160] [Reference Citation Analysis]
579 Denis M, Duruisseaux M, Brevet M, Dumontet C. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? Front Immunol 2020;11:492. [PMID: 32265935 DOI: 10.3389/fimmu.2020.00492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
580 Wang S, Zhang H, Liu C, Jiao X, Liu D, DU W, He Y, Zhang Z, Wu X, Wang J, Liang C, Zhang L, Liu S. Human leukocyte antigen-haploidentical donor-derived cytokine-induced killer cells are safe and prolong the survival of patients with advanced non-small cell lung cancer. Oncol Lett 2014;8:2727-33. [PMID: 25364456 DOI: 10.3892/ol.2014.2558] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
581 Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer 2020;122:555-63. [PMID: 31857723 DOI: 10.1038/s41416-019-0686-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
582 Klemen ND, Feingold PL, Goff SL, Hughes MS, Kammula US, Yang JC, Schrump DS, Rosenberg SA, Sherry RM. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Ann Surg Oncol 2017;24:135-41. [PMID: 27638681 DOI: 10.1245/s10434-016-5537-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
583 Savoia P, Astrua C, Fava P. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother 2016;12:1092-101. [PMID: 26889818 DOI: 10.1080/21645515.2015.1129478] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
584 Amin A, Lawson DH, Salama AK, Koon HB, Guthrie T Jr, Thomas SS, O'Day SJ, Shaheen MF, Zhang B, Francis S, Hodi FS. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer 2016;4:44. [PMID: 27532019 DOI: 10.1186/s40425-016-0148-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
585 Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. Int J Mol Sci 2019;20:E1631. [PMID: 30986912 DOI: 10.3390/ijms20071631] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
586 Harada K, Ogasawara M, Shido A, Meno A, Oda S, Yoshida S, Yoshida S, Yoshikawa A, Ebata K, Abiko S, Kawagishi N, Sano I, Oda H, Miyagishima T. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Thorac Cancer 2020;11:1350-3. [PMID: 32181993 DOI: 10.1111/1759-7714.13399] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
587 McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res 2014;20:3692-704. [PMID: 24850844 DOI: 10.1158/1078-0432.CCR-14-0169] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
588 Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 2016;5:1481-91. [PMID: 27167347 DOI: 10.1002/cam4.732] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
589 Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014;2:37-49. [PMID: 24535937 DOI: 10.1158/2326-6066.CIR-13-0126] [Cited by in Crossref: 130] [Cited by in F6Publishing: 83] [Article Influence: 16.3] [Reference Citation Analysis]
590 Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27. [PMID: 31154919 DOI: 10.1200/JCO.19.00934] [Cited by in Crossref: 271] [Cited by in F6Publishing: 164] [Article Influence: 90.3] [Reference Citation Analysis]
591 Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. Front Immunol 2018;9:411. [PMID: 29552014 DOI: 10.3389/fimmu.2018.00411] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
592 Vail DM, LeBlanc AK, Jeraj R. Advanced Cancer Imaging Applied in the Comparative Setting. Front Oncol 2020;10:84. [PMID: 32117739 DOI: 10.3389/fonc.2020.00084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
593 Zhang JQ, Zeng S, Vitiello GA, Seifert AM, Medina BD, Beckman MJ, Loo JK, Santamaria-Barria J, Maltbaek JH, Param NJ, Moral JA, Zhao JN, Balachandran V, Rossi F, Antonescu CR, DeMatteo RP. Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 2018;6:434-47. [PMID: 29467128 DOI: 10.1158/2326-6066.CIR-17-0345] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
594 Schliep S, Agaimy A, Cavallaro A, Kiesewetter F, Schuler G, Heinzerling L. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports. J Immunother Cancer 2018;6:2. [PMID: 29332608 DOI: 10.1186/s40425-017-0309-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
595 Tabei T, Nakaigawa N, Kaneta T, Ikeda I, Kondo K, Makiyama K, Hasumi H, Hayashi N, Kawahara T, Izumi K, Osaka K, Muraoka K, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Kobayashi K, Inoue T, Yao M. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer 2019;19:298. [PMID: 30940117 DOI: 10.1186/s12885-019-5510-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
596 Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR. A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res 2018;24:6288-99. [PMID: 30054278 DOI: 10.1158/1078-0432.CCR-17-3420] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
597 Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer 2018;124:3819-29. [PMID: 29723407 DOI: 10.1002/cncr.31517] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
598 Boland JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, Konner J, Callahan M, Friedman C, Aghajanian C, Sabbatini P, Zamarin D, Cadoo KA. Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecol Oncol 2020;158:303-8. [PMID: 32507515 DOI: 10.1016/j.ygyno.2020.04.710] [Reference Citation Analysis]
599 Lanitis T, Proskorovsky I, Ambavane A, Hunger M, Zheng Y, Bharmal M, Phatak H. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Adv Ther. 2019;36:2327-2341. [PMID: 31350728 DOI: 10.1007/s12325-019-01034-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
600 Xu Y, Li H, Fan Y. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Oncol 2021;11:642883. [PMID: 33747966 DOI: 10.3389/fonc.2021.642883] [Reference Citation Analysis]
601 Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett 2016;12:4493-504. [PMID: 28105158 DOI: 10.3892/ol.2016.5253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
602 Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017;35:2439-2449. [PMID: 28640707 DOI: 10.1200/jco.2017.72.7511] [Cited by in Crossref: 123] [Cited by in F6Publishing: 69] [Article Influence: 24.6] [Reference Citation Analysis]
603 Tsimberidou AM, Levit LA, Schilsky RL, Averbuch SD, Chen D, Kirkwood JM, McShane LM, Sharon E, Mileham KF, Postow MA. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer 2018;6:108. [PMID: 30340549 DOI: 10.1186/s40425-018-0426-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
604 Deniz B, Ambavane A, Yang S, Altincatal A, Doan J, Rao S, Michaelson MD. Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS One 2019;14:e0215761. [PMID: 31465470 DOI: 10.1371/journal.pone.0215761] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
605 Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M. Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. Clinicoecon Outcomes Res 2018;10:139-54. [PMID: 29563820 DOI: 10.2147/CEOR.S144208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
606 Scarpelli M, Zahm C, Perlman S, McNeel DG, Jeraj R, Liu G. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer 2019;7:23. [PMID: 30700328 DOI: 10.1186/s40425-019-0516-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
607 Fernandes M, Rosel D, Brábek J. Translation in solid cancer: are size-based response criteria an anachronism? Clin Transl Oncol 2015;17:1-10. [PMID: 25073600 DOI: 10.1007/s12094-014-1207-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
608 Kaufmann JK, Chiocca EA. Glioma virus therapies between bench and bedside. Neuro Oncol 2014;16:334-51. [PMID: 24470549 DOI: 10.1093/neuonc/not310] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
609 Vermeulen S, Awada G, Keyaerts M, Neyns B, Everaert H. Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Curr Oncol 2021;28:1630-40. [PMID: 33925392 DOI: 10.3390/curroncol28030152] [Reference Citation Analysis]
610 Chukwueke UN, Wen PY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol 2019;8:CNS28. [PMID: 30806082 DOI: 10.2217/cns-2018-0007] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 19.7] [Reference Citation Analysis]
611 Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16:2861-71. [PMID: 20460488 DOI: 10.1158/1078-0432.CCR-10-0569] [Cited by in Crossref: 315] [Cited by in F6Publishing: 169] [Article Influence: 26.3] [Reference Citation Analysis]
612 Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Krämer B, Grischke EM, Brucker SY. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care (Basel) 2016;11:385-90. [PMID: 28228704 DOI: 10.1159/000453569] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
613 Iyalomhe O, Farwell MD. Immune PET Imaging. Radiol Clin North Am 2021;59:875-86. [PMID: 34392924 DOI: 10.1016/j.rcl.2021.05.010] [Reference Citation Analysis]
614 Zimmer L, Vaubel J, Schadendorf D. [Immunotherapy of melanomas]. Hautarzt 2012;63:952-8. [PMID: 23097082 DOI: 10.1007/s00105-012-2470-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
615 Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov 2017;7:188-201. [PMID: 27903500 DOI: 10.1158/2159-8290.CD-16-1223] [Cited by in Crossref: 570] [Cited by in F6Publishing: 373] [Article Influence: 95.0] [Reference Citation Analysis]
616 Morgan B, Kennedy AS, Lewington V, Jones B, Sharma RA. Intra-arterial brachytherapy of hepatic malignancies: watch the flow. Nat Rev Clin Oncol. 2011;8:115-120. [PMID: 20924355 DOI: 10.1038/nrclinonc.2010.153] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
617 McGray AJR, Huang RY, Battaglia S, Eppolito C, Miliotto A, Stephenson KB, Lugade AA, Webster G, Lichty BD, Seshadri M, Kozbor D, Odunsi K. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. J Immunother Cancer 2019;7:189. [PMID: 31315674 DOI: 10.1186/s40425-019-0641-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
618 Clarke JM, George DJ, Lisi S, Salama AKS. Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Target Oncol 2018;13:1-20. [PMID: 29441437 DOI: 10.1007/s11523-017-0549-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
619 Jiang X, Dudzinski S, Beckermann KE, Young K, McKinley E, J McIntyre O, Rathmell JC, Xu J, Gore JC. MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. J Immunother Cancer 2020;8:e000328. [PMID: 32581044 DOI: 10.1136/jitc-2019-000328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
620 Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237-251. [PMID: 22437869 DOI: 10.1038/nrc3237] [Cited by in Crossref: 847] [Cited by in F6Publishing: 798] [Article Influence: 84.7] [Reference Citation Analysis]
621 Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer 2019;125:3208-18. [PMID: 31246283 DOI: 10.1002/cncr.32190] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
622 Fernández-Pérez G, Sánchez-Escribano R, García-Vicente AM, Luna-Alcalá A, Ceballos-Viro J, Delgado-Bolton RC, Vilanova-Busquets JC, Sánchez-Rovira P, Fierro-Alanis MP, García-Figueiras R, Alés-Martínez JE. SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. Clin Transl Oncol 2018;20:837-52. [PMID: 29256154 DOI: 10.1007/s12094-017-1795-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
623 Ascierto PA, Addeo R, Cartenì G, Daniele B, De Laurentis M, Ianniello GP, Morabito A, Palmieri G, Pepe S, Perrone F, Pignata S, Montesarchio V. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med 2014;12:291. [PMID: 25331657 DOI: 10.1186/s12967-014-0291-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
624 Fröhlich A, Hoffmann F, Niebel D, Egger E, Kukuk GM, Toma M, Sirokay J, Bieber T, Landsberg J. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. Front Oncol 2020;10:611. [PMID: 32457834 DOI: 10.3389/fonc.2020.00611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
625 Zhang P, Nie X, Bie Z, Li L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine (Baltimore) 2018;97:e0006. [PMID: 29489642 DOI: 10.1097/MD.0000000000010006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
626 Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. Eur J Cancer 2016;62:138-45. [PMID: 27237360 DOI: 10.1016/j.ejca.2016.03.082] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 13.5] [Reference Citation Analysis]
627 Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14:907-917. [PMID: 29260582 DOI: 10.2217/fon-2017-0531] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]
628 Hwang KE, Kim HR. Response Evaluation of Chemotherapy for Lung Cancer. Tuberc Respir Dis (Seoul) 2017;80:136-42. [PMID: 28416953 DOI: 10.4046/trd.2017.80.2.136] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
629 Liberini V, Laudicella R, Capozza M, Huellner MW, Burger IA, Baldari S, Terreno E, Deandreis D. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. Molecules 2021;26:2201. [PMID: 33920423 DOI: 10.3390/molecules26082201] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
630 Zhang Q, Chen Y, Bai X, Liang T. Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Front Oncol 2020;10:590058. [PMID: 33178615 DOI: 10.3389/fonc.2020.590058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
631 Swami U, Swick B, Zakharia Y, Milhem M. Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Rep Oncol Med 2019;2019:4683531. [PMID: 30963012 DOI: 10.1155/2019/4683531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
632 Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res 2013;32:82. [PMID: 24423086 DOI: 10.1186/1756-9966-32-82] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
633 Garcia D, Beal JR, Alvarez DM, Macarenco RSES, Schvartsman G. Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma. Case Rep Oncol 2021;14:881-5. [PMID: 34248554 DOI: 10.1159/000516036] [Reference Citation Analysis]
634 Chen M, Chen Z, Castillo JB, Cui L, Zhou K, Shen B, Xie J, Chin FT, Rao J. [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies. Eur J Nucl Med Mol Imaging 2021;48:3386-99. [PMID: 33712870 DOI: 10.1007/s00259-021-05297-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
635 Shao M, He DH, Cai Z. [Advances on PD-1/PD-L1 inhibitors in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2018;39:261-4. [PMID: 29562480 DOI: 10.3760/cma.j.issn.0253-2727.2018.03.022] [Reference Citation Analysis]
636 Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiol Imaging Cancer 2019;1:e190031. [PMID: 33778682 DOI: 10.1148/rycan.2019190031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
637 Ascierto PA. Combination therapies in advanced melanoma. Melanoma Manag 2014;1:47-56. [PMID: 30190810 DOI: 10.2217/mmt.13.1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
638 Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther. 2014;96:214-223. [PMID: 24690569 DOI: 10.1038/clpt.2014.74] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
639 Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11:504-514. [PMID: 26260659 DOI: 10.1038/nrneurol.2015.139] [Cited by in Crossref: 209] [Cited by in F6Publishing: 203] [Article Influence: 29.9] [Reference Citation Analysis]
640 Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, Thomas L, Lebbé C, Mortier L, Saiag P, Avril MF, Maubec E, Joly P, Bey P, Cosset JM, Sun JS, Asselain B, Devun F, Marty ME, Dutreix M. First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. Br J Cancer 2016;114:1199-205. [PMID: 27140316 DOI: 10.1038/bjc.2016.120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
641 Sarfaty M, Moore A, Dudnik E, Peled N. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report. Medicine (Baltimore) 2017;96:e5951. [PMID: 28121940 DOI: 10.1097/MD.0000000000005951] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
642 Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19:6678-6685. [PMID: 24030702 DOI: 10.1158/1078-0432.ccr-13-1721] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
643 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144. [PMID: 23724846 DOI: 10.1056/nejmoa1305133] [Cited by in Crossref: 2338] [Cited by in F6Publishing: 1367] [Article Influence: 259.8] [Reference Citation Analysis]
644 Ke L, Wu L, Yu J, Meng X. Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy. Nucl Med Commun 2021;42:1017-23. [PMID: 33899782 DOI: 10.1097/MNM.0000000000001428] [Reference Citation Analysis]
645 Bauckneht M, Genova C, Rossi G, Rijavec E, Dal Bello MG, Ferrarazzo G, Tagliamento M, Donegani MI, Biello F, Chiola S, Zullo L, Raffa S, Lanfranchi F, Cittadini G, Marini C, Lopci E, Sambuceti G, Grossi F, Morbelli S. The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers (Basel) 2021;13:3117. [PMID: 34206545 DOI: 10.3390/cancers13133117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
646 Chai LF, Prince E, Pillarisetty VG, Katz SC. Challenges in assessing solid tumor responses to immunotherapy. Cancer Gene Ther 2020;27:528-38. [PMID: 31822814 DOI: 10.1038/s41417-019-0155-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
647 Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015;34:823-42. [PMID: 26433592 DOI: 10.1007/s10555-015-9598-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
648 Gering D, Kotrotsou A, Young-Moxon B, Miller N, Avery A, Kohli L, Knapp H, Hoffman J, Chylla R, Peitzman L, Mackie TR. Measuring Efficiency of Semi-automated Brain Tumor Segmentation by Simulating User Interaction. Front Comput Neurosci 2020;14:32. [PMID: 32372938 DOI: 10.3389/fncom.2020.00032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer 2016;4:48. [PMID: 27532023 DOI: 10.1186/s40425-016-0153-x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 123] [Article Influence: 20.8] [Reference Citation Analysis]
650 Ratterman M, Hallmeyer S, Richards J. Sequencing of New and Old Therapies for Metastatic Melanoma. Curr Treat Options Oncol 2016;17:52. [PMID: 27515170 DOI: 10.1007/s11864-016-0427-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
651 Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 2018;6:111. [PMID: 30348224 DOI: 10.1186/s40425-018-0424-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 16.0] [Reference Citation Analysis]
652 Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 2016;13:171-93. [PMID: 27458526 DOI: 10.20892/j.issn.2095-3941.2016.0015] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
653 Wong A, Vellayappan B, Cheng L, Zhao JJ, Muthu V, Asokumaran Y, Low JL, Lee M, Huang YQ, Kumarakulasinghe NB, Ngoi N, Leong CN, Chua W, Thian YL. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri. Cancers (Basel) 2021;13:1689. [PMID: 33918397 DOI: 10.3390/cancers13071689] [Reference Citation Analysis]
654 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23. [PMID: 20525992 DOI: 10.1056/NEJMoa1003466] [Cited by in Crossref: 9387] [Cited by in F6Publishing: 4960] [Article Influence: 782.3] [Reference Citation Analysis]
655 GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res 2015;21:3619-30. [PMID: 25649018 DOI: 10.1158/1078-0432.CCR-14-2334] [Cited by in Crossref: 82] [Cited by in F6Publishing: 57] [Article Influence: 11.7] [Reference Citation Analysis]
656 Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 2011;17:372-8. [PMID: 21952288 DOI: 10.1097/PPO.0b013e31823261db] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
657 Saida Y, Brender JR, Yamamoto K, Mitchell JB, Krishna MC, Kishimoto S. Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. Cancer Res 2021;81:3693-705. [PMID: 33837042 DOI: 10.1158/0008-5472.CAN-20-3182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
658 Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol 2021. [PMID: 34750637 DOI: 10.1007/s00280-021-04358-3] [Reference Citation Analysis]
659 Guibert N, Mazieres J, Delaunay M, Casanova A, Farella M, Keller L, Favre G, Pradines A. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget 2017;8:38056-60. [PMID: 28445137 DOI: 10.18632/oncotarget.16935] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
660 Jatoi I, Benson JR, Kunkler I. Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality? NPJ Breast Cancer 2018;4:8. [PMID: 29644338 DOI: 10.1038/s41523-018-0061-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
661 Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res 2015;3:1185-92. [PMID: 26100356 DOI: 10.1158/2326-6066.CIR-15-0102] [Cited by in Crossref: 133] [Cited by in F6Publishing: 64] [Article Influence: 19.0] [Reference Citation Analysis]
662 Ulaner GA, Saura C, Piha-Paul SA, Mayer I, Quinn D, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clin Cancer Res 2019;25:7381-7. [PMID: 31548342 DOI: 10.1158/1078-0432.CCR-19-1658] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
663 Beer L, Hochmair M, Kifjak D, Haug AR, Prayer F, Mayerhoefer ME, Herold C, Prosch H. Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. Wien Klin Wochenschr. 2020;132:467-474. [PMID: 32430613 DOI: 10.1007/s00508-020-01667-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Skovgard MS, Hocine HR, Saini JK, Moroz M, Bellis RY, Banerjee S, Morello A, Ponomarev V, Villena-Vargas J, Adusumilli PS. Imaging CAR T-cell kinetics in solid tumors: Translational implications. Mol Ther Oncolytics 2021;22:355-67. [PMID: 34553024 DOI: 10.1016/j.omto.2021.06.006] [Reference Citation Analysis]
665 Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol 2018;151:407-13. [PMID: 30366646 DOI: 10.1016/j.ygyno.2018.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
666 Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, Phillips EJ. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol 2020;86:1778-89. [PMID: 32543711 DOI: 10.1111/bcp.14433] [Cited by in Crossref: 11] [</